<?xml version="1.0" encoding="UTF-8"?><TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:space="preserve" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Elsevier BV</publisher>
				<availability status="unknown"><p>Copyright Elsevier BV</p>
				</availability>
				<date type="published" when="2022-12-22">22 December 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Elda</forename><surname>Righi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Diagnostics and Public Health</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nico</forename><forename type="middle">T</forename><surname>Mutters</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute for Hygiene and Public Health</orgName>
								<orgName type="institution">University Hospital Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xavier</forename><surname>Guirao</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Parc Tauli</orgName>
								<orgName type="laboratory" key="lab1">Surgical Endocrine Unit</orgName>
								<orgName type="laboratory" key="lab2">Surgical Site Prevention Unit</orgName>
								<orgName type="institution">Hospital Universitari Sabadell</orgName>
								<address>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">Dolores</forename><surname>Del Toro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Eckmann</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Klinikum Hannoversch-Muenden</orgName>
								<orgName type="institution">Academic Hospital of Goettingen University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alex</forename><forename type="middle">W</forename><surname>Friedrich</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">University Medical Center Groningen</orgName>
								<orgName type="department" key="dep2">Department of Medical Microbiology and Infection Prevention</orgName>
								<orgName type="institution">University of Groningen</orgName>
								<address>
									<settlement>Groningen</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Institute for European Prevention Networks in Infection Control</orgName>
								<orgName type="institution">University Hospital Münster</orgName>
								<address>
									<settlement>Münster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maddalena</forename><surname>Giannella</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)</orgName>
								<orgName type="laboratory">Infectious Diseases Unit</orgName>
								<orgName type="institution">Azienda Ospedaliero Universitaria di Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Medical and Surgical Sciences</orgName>
								<orgName type="institution">University of Bologna</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Kluytmans</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Medical Microbiology</orgName>
								<orgName type="institution" key="instit1">University Medical Center Utrecht</orgName>
								<orgName type="institution" key="instit2">Utrecht University</orgName>
								<address>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Presterl</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Infection Control and Hospital Epidemiology</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eirini</forename><surname>Christaki</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="department" key="dep3">School of Health Sciences</orgName>
								<orgName type="institution">University of Ioannina</orgName>
								<address>
									<settlement>Ioannina</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elizabeth</forename><forename type="middle">L A</forename><surname>Cross</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Global Health and Infection</orgName>
								<orgName type="department" key="dep2">Brighton and Sussex Medical School</orgName>
								<address>
									<settlement>Brighton</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alessandro</forename><surname>Visentin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Diagnostics and Public Health</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriele</forename><surname>Sganga</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Emergency Surgery and Trauma</orgName>
								<orgName type="institution" key="instit1">Fondazione Policlinico Universitario A. Gemelli IRCCS</orgName>
								<orgName type="institution" key="instit2">Universit a Cattolica del Sacro Cuore</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Constantinos</forename><surname>Tsioutis</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">European University Cyprus</orgName>
								<address>
									<settlement>Nicosia</settlement>
									<country key="CY">Cyprus</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Evelina</forename><surname>Tacconelli</surname></persName>
							<email>evelina.tacconelli@univr.it</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Diagnostics and Public Health</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine I</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Infectious Diseases Division</orgName>
								<orgName type="department" key="dep2">Di-agnostics and Public Health Department</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<addrLine>P.le L.A. Scuro 10</addrLine>
									<postCode>37134</postCode>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Clinical Microbiology and Infection</title>
						<title level="j" type="abbrev">Clinical Microbiology and Infection</title>
						<idno type="ISSN">1198-743X</idno>
						<imprint>
							<publisher>Elsevier BV</publisher>
							<biblScope unit="volume">29</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page" from="463" to="479"/>
							<date type="published" when="2022-12-22">22 December 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">3FE54F0CA9F2A2745836946D6EAA40AD</idno>
					<idno type="DOI">10.1016/j.cmi.2022.12.012</idno>
					<note type="submission">Received 12 September 2022 Received in revised form 10 December 2022 Accepted 11 December 2022</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-06-16T16:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>ESCMID GRADE Multidrug-resistant Gram-negative bacteria Perioperative antibiotic prophylaxis Rectal colonization Surgical site infections</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>a b s t r a c t Scope: The aim of the guidelines is to provide recommendations on perioperative antibiotic prophylaxis (PAP) in adult inpatients who are carriers of multidrug-resistant Gram-negative bacteria (MDR-GNB) before surgery. Methods: These evidence-based guidelines were developed after a systematic review of published studies on PAP targeting the following MDR-GNB: extended-spectrum cephalosporin-resistant Enterobacterales, carbapenem-resistant Enterobacterales (CRE), aminoglycoside-resistant Enterobacterales, fluoroquinolone-resistant Enterobacterales, cotrimoxazole-resistant Stenotrophomonas maltophilia, carbapenem-resistant Acinetobacter baumannii (CRAB), extremely drug-resistant Pseudomonas aeruginosa, colistin-resistant Gram-negative bacteria, and pan-drug-resistant Gram-negative bacteria. The critical outcomes were the occurrence of surgical site infections (SSIs) caused by any bacteria and/or by the colonizing MDR-GNB, and SSI-attributable mortality. Important outcomes included the occurrence of any type of postsurgical infectious complication, all-cause mortality, and adverse events of PAP, including development of resistance to targeted (culture-based) PAP after surgery and incidence of Clostridioides difficile infections. The last search of all databases was performed until <ref type="bibr">April 30, 2022</ref>. The level of evidence and strength of each recommendation were defined according to the Grading of Recommendations Assessment, Development and Evaluation approach. Consensus of a multidisciplinary expert panel was reached for the final list of recommendations. Antimicrobial stewardship considerations were included in the recommendation development.</p><p>Recommendations: The guideline panel reviewed the evidence, per bacteria, of the risk of SSIs in patients colonized with MDR-GNB before surgery and critically appraised the existing studies. Significant knowledge gaps were identified, and most questions were addressed by observational studies. Moderate to high risk of bias was identified in the retrieved studies, and the majority of the recommendations were supported by low level of evidence. The panel conditionally recommends rectal screening and targeted PAP for fluoroquinolone-resistant Enterobacterales before transrectal ultrasound-guided prostate biopsy and for extended-spectrum cephalosporin-resistant Enterobacterales in patients undergoing colorectal surgery and solid organ transplantation. Screening for CRE and CRAB is suggested before transplant surgery after assessment of the local epidemiology. Careful consideration of the laboratory workload and involvement of antimicrobial stewardship teams before implementing the screening procedures or performing changes in PAP are warranted. High-quality prospective studies to assess the impact of PAP among CRE and CRAB carriers performing high-risk surgeries are advocated. Future well-designed clinical trials should assess the effectiveness of targeted PAP, including the monitoring of MDR-GNB colonization through postoperative cultures using European Committee on Antimicrobial Susceptibility Testing clinical breakpoints. <ref type="bibr">Elda</ref>  Diseases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Scope and context</head><p>The World Health Organization (WHO) has defined, among multidrug-resistant Gram-negative bacteria (MDR-GNB), carbapenem-resistant Acinetobacter baumannii (CRAB), CR Pseudomonas aeruginosa (CRPA), CR Enterobacterales (CRE) such as Klebsiella pneumoniae (CRKP) as well as extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) as bacteria of critical importance for research and development of new antibiotics <ref type="bibr" target="#b0">[1]</ref>. An insufficient antibiotic pipeline, substantial healthcare burden, and partly effective or not well-defined preventability in the healthcare setting were among the prioritizing criteria for MDR-GNB selection in the WHO list <ref type="bibr" target="#b0">[1]</ref>. In the hospital setting, infection risks for surgical site infections (SSIs) development are well characterized and classified according to patient and procedural factors such as age, comorbidities, surgery type, degree of wound contamination, and duration of surgery <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>. Furthermore, SSIs represent frequent postoperative complications, ranging from 10% to 25% according to the type of surgery in prospective clinical studies, and have a negative impact on patients' morbidity, mortality, and associated healthcare costs <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>. The increase of antimicrobial resistance at global level has also affected SSIs, leading to prolonged hospitalization, extended duration of antibiotic treatment, need for surgical revisions, and increased mortality <ref type="bibr" target="#b5">[6]</ref>. A meta-analysis investigating the efficacy of perioperative antibiotic prophylaxis (PAP) in colorectal surgery showed that SSIs steadily increased between 1980 and 2005, irrespective of the type of PAP or surgical technique <ref type="bibr" target="#b6">[7]</ref>. The reduction in PAP efficacy could be explained by a rise in the intestinal colonization with resistant Enterobacterales that may not be covered by routine PAP, usually including a cephalosporin combined with metronidazole to target the aerobic and anaerobic intestinal microbiota <ref type="bibr" target="#b4">[5]</ref>. Increasing rates of SSIs caused by MDR-GNB have been reported [8e10] along with emerging evidence that rectal colonization precedes infection <ref type="bibr">[11e14]</ref>. Decolonization of MDR-GNB carriers before surgery is not routinely recommended owing to the lack of long-term efficacy and the potential risk for antibiotic resistance selection <ref type="bibr" target="#b14">[15]</ref>. The 2013 European Centre for Disease Prevention and Control (ECDC) guidance suggests that periodical active surveillance of MDR bacteria should be performed by trained personnel to adjust the selection of PAP <ref type="bibr" target="#b15">[16]</ref>. To date, no other international guidelines have provided specific recommendations on targeted PAP for MDR-GNB carriers <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18]</ref>. The WHO guidelines on the prevention of SSIs, reviewing studies up to 2015, did not advise for or against MDR-GNB rectal screening and/or culture-directed PAP, and concern about presurgical ESCR-E screening implementation as a potential risk for carbapenembased PAP and CRE selection has been raised <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b18">19]</ref>.</p><p>The objective of these guidelines is to provide evidence-based recommendations for PAP in adult inpatients with preoperative MDR-GNB rectal colonization, with no restrictions on the type of surgery or associated comorbidities. Anticipated users include surgeons, anaesthetists, infection control and infectious diseases specialists, clinical microbiologists, hospital staff (e.g. clinical medical, nursing, and paramedical staff), and policy makers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Questions addressed by the guidelines</head><p>The target MDR-GNB (listed in the subsequent section) and the guideline questions were selected by consensus during the first panel meeting. To address the benefits of presurgical screening for MDR-GNB to inform targeted PAP in carriers before surgery, the articles reporting the rates of postoperative infections in MDR-GNB carriers vs. noncarriers were reviewed.</p><p>Sampling techniques and microbiological practices were not reviewed or discussed because they were beyond the scope of these guidelines.</p><p>The main research questions addressed by the guidelines include:</p><p>1. Should screening for MDR-GNB be recommended before surgery and when? 2. Which PAP have been evaluated for patients colonized with the target MDR-GNB? 3. Should PAP be adapted in patients colonized with MDR-GNB before surgery? 4. Should other interventions, such as decolonization therapy,</p><p>preoperative digestive decontamination (PDD), or bundled interventions be performed as a potential adjunct to PAP in MDR-GNB carriers before surgery? 5. Should the duration of PAP change in patients colonized with MDR-GNB before surgery?</p><p>The recommendations are summarized in Table <ref type="table" target="#tab_1">1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>These guidelines were developed by a multidisciplinary group of experts including infectious diseases specialists, clinical microbiologists, and surgeons, according to the ESCMID guidance document (www.escmid.org). The panel reviewed the articles and discussed evidence-based tables, evidence certainty classification, and recommendation strength. The recommendations were revised until consensus was reached, and the final list of recommendations was approved by the whole panel.</p><p>Please see Supplementary Material for details on the guideline development. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Literature search and data extraction</head><p>A systematic review of the published literature was performed, including studies evaluating PAP in adult inpatients (aged 18 years) colonized with MDR-GNB before surgery. The review protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and was registered on the International Prospective Register of Systematic Reviews (PROSPERO -N. CRD42021170244) <ref type="bibr" target="#b19">[20]</ref>.</p><p>Because of the expected limited number of randomized controlled trials (RCTs), any type of study except for case reports was reviewed. Data retrieved exclusively from outpatients and from pediatric populations as well as studies omitting patients' carrier status before surgery were excluded. The articles were identified through literature searches using Medline, Embase, and Cochrane databases from January 2010 to December 2021. The search started from January 2010 because the existing guidelines reported no evidence to support the screening for MDR-GNB and targeted PAP up to 2010 and 2015 <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b4">5]</ref>. A focused search for any recently published, relevant study was also performed from January until April 30, 2022, using Medline and Google Scholar. References from the retrieved articles were screened for potential inclusion in the review.</p><p>A combination of Medical Subject Headings and equivalent terms as well as keywords were used for each MDR-GNB, as detailed in the Supplementary Material (Appendix S1), and a twostage selection process was performed by two independent reviewers (E.L.A.C. and A.V.). All retrieved abstracts were screened against eligibility criteria and duplicates were discarded. If eligibility could not be determined, the full article was retrieved. Disagreements were resolved by consultation with a third party (E.C. and further reviewed by E.R. and N.M.). Flowcharts of assessed studies are reported in Appendix S1.</p><p>Data were extracted into a predefined Excel database to record the study relevant features, specifically: country and year of publication, study design, type of surgery, target bacteria, type of culture-directed (reported as "targeted") PAP, and outcomes.</p><p>A PICO (population/participant, intervention, comparator/control, outcome) framework was implemented defining the following elements:</p><p>1. Population: adult surgical inpatients with screening samples obtained before surgery yielding one of the following MDR-GNB: (a) ESCR-E, (b) CRE, (c) aminoglycoside-resistant Enterobacterales (AGRE), (d) fluoroquinolone-resistant Enterobacterales (FQR-E), (e) extremely drug-resistant Pseudomonas aeruginosa (XDRPA), (f) cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), (g) CRAB, (h) colistinresistant GNB (CoRGNB), (i) pan-drug-resistant GNB (PDR-GNB). According to the 2012 international consensus definitions <ref type="bibr" target="#b20">[21]</ref>, MDR was defined as nonsusceptibility to at least one agent in three or more antibiotic classes, "extremely drugresistant" was defined as nonsusceptibility to at least one agent in all but two or fewer antibiotic classes, and pandrug-resistant as nonsusceptibility to all licensed and routinely available antibiotics. 2. Intervention: targeted PAP, defined as a regimen selected according to bacterial culture results and their susceptibility pattern (or predefined according to the effective antibiotic) to target the colonizing MDR-GNB. A section of these guidelines is dedicated to MDR-GNB colonized solid organ transplant (SOT) recipients. Urologic surgery recommendations are discussed in a separate section because of the specific characteristics associated with this type of surgery.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality assessment and grading recommendations</head><p>The risk of bias of the included studies is reported in Appendix S2. The quality assessment was performed using the Effective Practice and Organization of Care guidelines for RCTs and the Newcastle-Ottawa Scale for uncontrolled studies (Appendix S1) <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>. The certainty of evidence was classified as high, moderate, low, or very low, and the strength of recommendations was reported as strong or conditional (weak) according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system <ref type="bibr" target="#b23">[24]</ref>. According to GRADE, good practice statements were designated based on expert opinion and reported as ungraded <ref type="bibr" target="#b24">[25]</ref>.</p><p>Further research propositions, indications for infection prevention, and antimicrobial stewardship considerations were not developed formally and therefore were not graded.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>The guidelines are reported according to the colonizing bacteria, except for organ transplant surgery and urologic surgery for which, because of the specific characteristics and type of associated infections, an additional section was added. Each section reports the questions addressed by the guidelines, the recommendations graded according to the available evidence, and the recommendations for research. If relevant, infection prevention and stewardship considerations were also reported.</p><p>No RCTs were available for inclusion. Regarding question 4, no articles targeting MDR-GNB carriers through decolonization protocols, PDD, or bundled interventions before surgery were retrieved.</p><p>Reports comparing SSIs or, in general, postoperative infections between colonized and noncolonized patients before surgery included seven observational studies for ESCR-E, four for CRE, and two for CRAB (Table <ref type="table" target="#tab_3">2</ref>) <ref type="bibr">[12,13,26e35]</ref>, mainly with moderate or high risk of bias (Appendix 2). No evidence was found for XDRPA, AGRE, CRSM, CoRGNB, or PDR-GNB. Very few reports directly compared the efficacy of targeted with that of routine PAP in reducing postoperative infections among MDR-GNB carriers and are summarized in Appendix S2. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>E. Righi et al. / Clinical Microbiology and Infection 29 (2023) 463e479</head><p>Table <ref type="table">3</ref> Options for perioperative antibiotic prophylaxis regimens for targeted prophylaxis in MDR-GNB carriers</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MDR-GNB colonization type</head><p>Regimen for culture-based approach a</p><p>Intraoperative dosing b</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>WHO AWaRe class</head><p>Comments and clinical use c</p><p>ESCR-E Ampicillin/sulbactam 3 g IV <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> Every 2-4 hours <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> Access Use alternatives in penicillin allergic Postoperative dosing every 6-8 hours Amoxicillin/clavulanate IV alternative <ref type="bibr" target="#b4">[5]</ref> For ESCR-E treatment, ESCMID guidelines conditionally recommend amoxicillin/clavulanate for low-risk, non-severe infections (moderate certainty of evidence) and for stepdown targeted therapy (good practice statement) <ref type="bibr" target="#b39">[40]</ref>; not enough evidence for ampicillin/sulbactam recommendations Gentamicin 5 mg/kg IV <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> d Access Used in case of penicillin allergy <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> Amikacin alternative <ref type="bibr" target="#b4">[5]</ref> Consider avoiding aminoglycosides in combination with other nephrotoxic drugs or in case of renal dysfunction <ref type="bibr" target="#b4">[5]</ref> Administer in addition to anaerobic coverage (according to the type of surgery and allergic status) <ref type="bibr" target="#b4">[5]</ref> For ESCR-E treatment, ESCMID guidelines conditionally recommend aminoglycosides for short treatments in non-severe infections (e.g., UTIs; moderate certainty of evidence) [40] Ciprofloxacin 400 mg IV <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> d Watch Levofloxacin IV alternative <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> Administered in addition to anaerobic coverage (according to the type of surgery and allergic status) Postoperative dosing every 12 hours For ESCR-E treatment, ESCMID guidelines conditionally recommend quinolones for low-risk, non-severe infections (moderate certainty of evidence) and for stepdown targeted therapy (good practice statement) [40] Ertapenem 1 g IV <ref type="bibr" target="#b4">[5]</ref> d Watch Due to antimicrobial stewardship considerations, limit carbapenem use if alternatives available <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b44">45]</ref> Preferred to meropenem/imipenem due to 1. single administration, 2. reserve other carbapenems for severe infections <ref type="bibr" target="#b39">[40]</ref> Caution in suspect immediate hypersensitivity to beta-lactams For ESCR-E treatment, ESCMID guidelines recommends carbapenems as preferred regimen for severe infections; for BSIs without septic shock ertapenem may be preferred to imipenem or meropenem (conditional recommendation, moderate certainty of evidence) <ref type="bibr" target="#b39">[40]</ref> Piperacillin/tazobactam 3.375-4.5 g IV <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref> Every 2-4 hours <ref type="bibr">[</ref>  The table reports antibiotic regimens with dosing recommended by previous guidelines on perioperative surgical prophylaxis (including guidelines that do not specifically address MDR-GNB colonization before surgery) <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18]</ref>.</p><p>For culture-based approach, susceptibility should be confirmed by susceptibility test. Antibiotic regimens are reported in alphabetical order and according to the WHO AWaRe class (Access, Watch, and Reserve) <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref>. Dosing reported for adults &gt;40 Kg with normal renal function. Obesity and renal impairment may require dose adjustments <ref type="bibr" target="#b4">[5]</ref>.</p><p>PAP should be administered within 60 minutes before the incision (for fluoroquinolones and vancomycin the infusion should be started 120 minutes prior to incision) <ref type="bibr" target="#b4">[5]</ref>.</p><p>a For culture-based approach, local stewardship protocols should be considered if multiple alternatives are available.</p><p>b Intraoperatively redosing may be necessary depending on the duration of the procedure, the half-life of the antibiotics employed and should be considered in patients who have significant blood loss during surgery <ref type="bibr" target="#b4">[5]</ref>.</p><p>c Clinical use: ESCMID recommendations for the use of the indicated regimens in the treatment of ESCR-E are reported <ref type="bibr" target="#b39">[40]</ref>. </p><formula xml:id="formula_0">E</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery (conditional recommendation for use, low certainty of evidence).</p><p>We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing liver transplant surgery (conditional recommendation for use, very low certainty of evidence).</p><p>It might be a good practice to consider targeted PAP for all SOT recipients who are colonized with ESCR-E before surgery (ungraded good practice statement).</p><p>Specific aspects of PAP in SOT recipients are discussed in the following sections.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antimicrobial stewardship considerations</head><p>Regimens that may be used for targeted PAP in ESCR-E carriers are listed in Table <ref type="table">3</ref> according to the potential impact on antimicrobial resistance following the WHO Access, Watch, and Reserve (AWaRe) classification <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref> and considering the current indications for the treatment of MDR-GNB <ref type="bibr" target="#b39">[40]</ref>.</p><p>Under the consideration of antimicrobial stewardship, the use of carbapenems should be limited if other antibiotic options are available against ESCR-E. Reserve antibiotics that may be used for the treatment of extensively resistant bacteria, including novel molecules (e.g. ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol, imipenem-relebactam), should not be routinely used for targeted PAP in ESCR-E carriers <ref type="bibr" target="#b39">[40]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Targeted PAP in ESCR-E carriers. Two reports, including a prospective multinational study and a retrospective, single-centre study (with low and high risk of bias, respectively) analysed targeted PAP effectiveness in reducing postoperative infections <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b40">41]</ref>. Nutman et al. performed a multicenter, non-randomized, non-blinded interventional study involving three hospitals in Israel, Serbia, and Switzerland between 2012 and 2017 and including 3600 patients screened before elective colorectal surgery <ref type="bibr" target="#b40">[41]</ref>. Of these, 14% (9%e 29%) were ESCR-E carriers and 468 received either routine PAP with cefuroxime, or cefazolin, or ceftriaxone plus metronidazole (baseline phase) or ertapenem (interventional phase). There was a suboptimal adherence to the study phases, with 4% of patients receiving ertapenem in the baseline phase, 20% receiving routine PAP in the interventional phase, and 1% receiving other or no antibiotics. Patients receiving routine PAP had higher National Nosocomial Infections Surveillance (NNIS) scores, while increased stoma creation was reported in the ertapenem group. The multivariable model (including NNIS score and stoma creation) showed a decreased SSIs risk of 33%, with a statistically significant difference favouring ertapenem (adjusted risk difference, ARD e7.7%, 95% CI e14.6% to e0.8%). Moreover, SSIs caused by ESCR-E were significantly lower in the ertapenem (0.9%) compared with the routine PAP group (6.5%, ARD e5.6%, 95% CI, e8.9% to e2.3%) showing an 86% reduction. The NNT to prevent one SSI among ESCR-E carriers was 13. The number needed to screen to prevent one SSI ranged from 45 to 138 by study site. The study was underpowered to detect the effect of the intervention on deep SSIs. No differences in mortality, C. difficile infection, acute renal failure, or intensive care unit (ICU) admission were detected between groups. Overall length of hospital stay and emergence of antibiotic resistance were not reported <ref type="bibr" target="#b40">[41]</ref>. In a related, nested study from the same group including 225 patients at a single site, colonization by ESCR-E and CRE after surgery was significantly lower in the ertapenem vs. the routine arm <ref type="bibr" target="#b41">[42]</ref>.</p><p>Logre et al. <ref type="bibr" target="#b31">[32]</ref> retrospectively analysed 100 ESCR-E colonized LTR in France. A total of 35 postoperative infections caused by ESCR-E (11 SSIs, 10 urinary tract infections, nine pulmonary infections, and five sepsis) were reported at day 30. Only 68 patients could be assessed according to PAP, showing higher rates of ESCR-E postoperative infections among LTR receiving routine (7/11, 63%) compared with targeted (17/57, 30%) PAP (P¼ 0.04). Targeted PAP included cefoxitin (40%), a carbapenem (31%), or piperacillin/ tazobactam (29%). Although the results favoured targeted PAP, the quality of the study was low, with high risk of bias because of the retrospective nature, the limited sample size (with only 11 patients receiving routine prophylaxis), and the lack of outcome according to each regimen. Mortality rates between infected and noninfected patients at day 28 and 90 were similar, while ICU stay was longer in infected versus noninfected patients (P &lt; 0.001). Hospital length of stay and PAP-associated adverse effects or antibiotic resistance were not reported <ref type="bibr" target="#b31">[32]</ref>.</p><p>Other two reports on targeted PAP were analysed but showed major limitations. Apisarnthanarak et al. <ref type="bibr" target="#b29">[30]</ref> reported no association between the use of carbapenem-based PAP, received by 23% of carriers and 6% of noncarriers, and SSIs reduction (aOR, 0.89; 95% CI, 0.55-14.24); however, no comparison with other PAP was provided. De Pastena et al. <ref type="bibr" target="#b30">[31]</ref> performed an interventional nonrandomized prospective study in 76 ESCR-E carriers undergoing pancreatic surgery, comparing postoperative infections in patients receiving PAP with ampicillin/sulbactam (period 1) or piperacillin/ tazobactam (period 2). Although significantly higher rates of postoperative infections (30% versus 11%, P¼ 0.025) and superficial SSIs (34% versus 0, P &lt; 0.001) were shown in period 1 versus 2, PAP was not selected according to preoperative cultures, and prolonged PAP (up to 3 days) was allowed during period 1 in case of biliary stent placement <ref type="bibr" target="#b30">[31]</ref>.</p><p>Given the paucity of data and the observational study design, there was a low (for colorectal surgery) to very low (for liver transplant surgery) certainty of evidence supporting targeted PAP in ESCR-E carriers. Owing to the high risk for infections in SOT recipients and the evidence for liver transplant surgery, the panel believes it may be a good practice to consider targeted PAP for all SOT.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>Owing to the very low evidence for targeted PAP effectiveness in ESCR-E carriers undergoing liver transplantation and the lack of evidence for other transplant surgeries, further studies are needed to investigate the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates. Research protocols should include the postsurgical monitoring of antibiotic resistance (e.g. CRE colonization through rectal cultures, especially if carbapenem-based PAP is used) and report antimicrobial susceptibility according to the European Committee on Antimicrobial Susceptibility Testing (https://www.eucast.org/ clinical_breakpoints/) results.</p><p>Furthermore, due to the limited evidence on the effectiveness of targeted PAP in other specific surgical groups, the panel suggests designing clinical trials in ESCR-E carriers undergoing highrisk surgical procedures (e.g. major cardiothoracic surgery, pancreatic surgery, major oncologic general surgery or gynecologic surgery). The trial design should consider the local burden of ESCR-E and patient-related risk factors for carrier status (e.g. previous ESCR-E infections, recent use of broad-spectrum antibiotics, previous hospital or long-term care facility admission or prolonged stay, ICU stay, mechanical ventilation, renal failure). Postsurgical monitoring of resistance development to the antibiotics used for targeted regimens is recommended. Same-strain colonization and infection relatedness, as well as the mechanisms of resistance of newly isolated MDR-GNB detected after surgery, should be investigated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Carbapenem-resistant Enterobacterales</head><p>Question 2.1: Should patients be screened for carbapenem-resistant Enterobacterales (CRE) before surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>We suggest implementing rectal screening to identify CRE carriers before liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence).</p><p>It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRE before surgery (ungraded good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infection and prevention considerations</head><p>1. Any change in screening procedures should follow a careful assessment of local prevalence of CRE colonization and infection among patients admitted or transferred to the surgical wards; although a prevalence threshold is not clearly defined to recommend the implementation of screening procedures, it is reasonable to consider a prevalence 10% as a cut-off for implementation evaluation according to previous recommendation <ref type="bibr" target="#b2">[3]</ref>. 2. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. 3. Irrespective of the PAP, the panel considers the knowledge of the colonization status before SOT essential for the early implementation of infection control procedures (e.g. reducing the risk of intrahospital and community spreading).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Infections in CRE carriers versus noncarriers. Four observational studies (two retrospective, with high and medium risk of bias and two prospective, with medium risk of bias), all including LTR, three performed in Italy and one in Brazil, compared the rates of postoperative infections between CRE carriers and noncarriers ( </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>There is insufficient evidence for or against targeted PAP for patients who are colonized with CRE before surgery at the time of writing and therefore no recommendation can be issued.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Targeted PAP in CRE carriers. Two retrospective studies, a Brazilian single-centre study and a multicentric study performed in the US and Brazil (with moderate and high risk of bias, respectively) were retrieved <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b43">44]</ref>. In a cohort of 762 LTR enrolled between 2010-2018, PAP was changed from 2014 replacing cefotaxime with amikacin (in association with ampicillin) if an increased risk of developing MDR infections (e.g. vancomycin-resistant enterococci, CRAB, and CRE) was documented <ref type="bibr" target="#b12">[13]</ref>. Risk factors included pretransplant CRE colonization, treatment with a broad-spectrum antibiotic in the past 30 days, need of dialysis, or MELD &gt;24. A total of 229 (30%) SSIs were detected, including 109 caused by MDR bacteria. When targeted PAP was performed, the rates of SSIs caused by any MDR bacteria decreased to 13% (14/109) compared with 30% (25/120) of those caused by nonresistant bacteria (OR 0.35, 95% CI 0.15-0.80). The study, however, was limited by the lack of susceptibility profiles for MDR bacteria receiving targeted PAP and by the lack of data for CRE infections, therefore the efficacy of the modified PAP could not be clearly assessed <ref type="bibr" target="#b12">[13]</ref>. Taimur et al. <ref type="bibr" target="#b43">[44]</ref> included 60 SOT recipients (50% liver, 28% heart, and 12% kidney transplant recipients) with either previous CRE infection or carrier status. Post-transplant CRE infections were documented in 40% of cases, and 35% SOT recipients received targeted PAP for CRE. Targeted PAP, however, was not known for most patients and mainly consisted of a combination of 2 to 3 agents such as carbapenems, polymyxins, and tigecycline. At univariable analysis, targeted PAP was more commonly reported in patients with post-SOT CRE infections (13/24, 54%) compared with those without CRE infections (8/36, 22%, P¼ 0.015). Study limitations included the small sample size and the associated impossibility to perform a multivariable analysis. Furthermore, data on CRE colonization could not be dissected from previous CRE infection, and most patients on targeted prophylaxis had prior CRE bacteraemia <ref type="bibr" target="#b43">[44]</ref>. None of the studies provided data on adverse events or emergence of antibiotic resistance following targeted PAP. No conclusions could be drawn from these studies on the effects of targeted PAP in CRE carriers undergoing transplant surgery.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antimicrobial stewardship considerations</head><p>Although there is no evidence for recommending targeted PAP for CRE carriers, the knowledge of CRE colonization in high-risk patients, such as those receiving transplant surgery, is relevant not only for infection control purposes but also for the adaption of postsurgical empirical treatment, for example in case of severe infections <ref type="bibr" target="#b44">[45]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>The panel recommends designing clinical trials to assess the impact of CRE rectal screening in high-risk surgeries. A recommendation is made also to design trials of targeted PAP in CRE carriers undergoing SOT and other high-risk surgical procedures to evaluate the effectiveness, applicability, and safety of the intervention following antimicrobial stewardship principles, specifically: clinical trials of targeted PAP should be designed considering rectal culture results the choice of targeted PAP should take into consideration the limited number of options that are available for the treatment of CRE infections, avoiding novel compounds that may be required for the treatment of postsurgical infections Resistance monitoring should be performed through detection of MDR-GNB carriage after surgery and to detect emerging resistance to the regimens used for targeted PAP. In SSIs, the clonal relationship between MDR bacteria detected after surgery and preoperative colonizing bacteria should be determined, and both short-and long-term postsurgical colonization investigated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Carbapenem-resistant Acinetobacter baumannii (CRAB)</head><p>Question 3.1: Should patients be screened for CRAB before surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>We conditionally recommend implementing rectal screening to identify CRAB carriers before liver transplant surgery according to the local epidemiology (conditional recommendation, low certainty of evidence).</p><p>It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery (ungraded good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infection and prevention considerations</head><p>1. Any change in screening procedures should follow a careful assessment of local prevalence of CRAB colonization and infection among patients admitted or transferred to the surgical wards; although a prevalence threshold is not clearly defined to recommend the implementation of screening procedures, it is reasonable to consider a prevalence 10% as a cut-off for implementation evaluation according to previous recommendation <ref type="bibr" target="#b2">[3]</ref>.</p><p>2. Any change in procedures should consider evidenced-based screening protocols, including the screening of different body sites (e.g. skin) <ref type="bibr" target="#b45">[46]</ref>. 3. The choice of targeted versus universal screening should be based on the local work organization and integrated within antibiotic and diagnostic stewardship guidance. 4. The panel considers the knowledge of the colonization status of the patient before SOT essential for early implementation of infection control procedures (e.g. reducing the risk of intrahospital and community spreading).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Infections in CRAB carriers versus noncarriers. Only two cohort studies (one prospective and one retrospective with medium and high risk of bias, respectively), performed at the same transplant centre in Brazil, assessed CRAB postoperative infections among LTR <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b34">35]</ref> showing increased infection risk in carriers vs. noncarriers (Table <ref type="table" target="#tab_3">2</ref>). In the first study, 24 CRAB carriers were identified among 196 LTR <ref type="bibr" target="#b34">[35]</ref>. Post-LT infections caused by CRAB were detected in 56 (29%) LTR and associated with 60-day mortality (P &lt; 0.001). Pretransplant colonization was predictive of post-LT CRAB infection (relative risk, RR, 1.48, 95% CI 0.96-2.26) and mortality (RR 1.12, 95% CI 0.99-1.26) but was confirmed only by univariable analysis. In 7/ 11 carriers developing CRAB infections, pre-LT and post-LT strains appeared closely related by pulsed-field gel electrophoresis analysis <ref type="bibr" target="#b34">[35]</ref>. The second study reported pretransplant CRAB colonization in 28 out of 762 (4%) LTR with occurrence of CRAB SSIs in 31 (10%) patients. The rates of CRAB SSIs were significantly higher among CRAB carriers versus noncarriers (P¼ 0.001) <ref type="bibr" target="#b12">[13]</ref>.</p><p>Question 3.2: Should PAP be adapted in patients colonized with CRAB before surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>There is insufficient evidence for or against targeted PAP for patients who are colonized with CRAB before surgery at the time of writing and therefore no recommendation can be issued.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Targeted PAP in CRAB carriers. Freire et al. <ref type="bibr" target="#b34">[35]</ref> performed routine PAP with ampicillin plus cefotaxime in 18 out of 22 CRAB carriers receiving LT and targeted PAP (by addition of polymyxins to ampicillin plus cefotaxime) only in four patients; 2 out of 4 LTR receiving targeted PAP acquired postoperative CRAB infections with polymyxin MIC &gt;16 mg/dL, while no outcome data were reported for the others. Since data were retrieved from four patients, no conclusions could be drawn on targeted PAP in CRAB colonized patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antimicrobial stewardship considerations</head><p>Although there is no evidence for recommending targeted PAP for CRAB carriers, the knowledge of CRAB colonization in high-risk patients such as those receiving transplant surgery is relevant not only for infection control purposes but also for the adaption of postsurgical empirical treatment, for example in case of severe infections <ref type="bibr" target="#b44">[45]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>Due to the limited evidence that CRAB colonization before surgery increases the risk of postoperative CRAB infections, the panel suggests designing clinical trials comparing the incidence risk of CRAB infections in carriers versus noncarriers, especially for patients undergoing high-risk surgery. The efficacy of targeted versus routine PAP in CRAB carriers should be also investigated in clinical trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Timing for preoperative MDR-GNB screening</head><p>Question 4. When should we perform the screening for MDR-GNB before surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>For MDR-GNB screening, cultures performed within 3 weeks prior to surgery may be considered (ungraded good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>There were no studies evaluating the incidence of SSIs or other clinical outcomes according to the timing of preoperative screening. In the retrieved studies, rectal screening to detect MDR-GNB carriage was usually performed starting from 2 to 3 weeks before surgery until the day of surgery, while some reports did not specify the timing for preoperative screening (Table <ref type="table" target="#tab_3">2</ref>). Colonization remains a dynamic process with long-term persistence of MDR-GNB carriage status that may occur in patients discharged by hospitals and those undergoing surgery, including SOT <ref type="bibr" target="#b46">[47,</ref><ref type="bibr" target="#b47">48]</ref>. Data favoring targeted PAP based on the results of cultures taken more than 3 weeks before surgery were not retrieved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>Studies analyzing the optimal timing for preoperative screening should be performed. Further research should evaluate the benefits of additional before surgery in case of recent antibiotic treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Duration of PAP in MDR-GNB carriers</head><p>Question 5. Should the duration of PAP change in patients colonized with MDR-GNB before surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB (strong recommendation, moderate certainty of evidence).</p><p>In transplant surgery other than renal transplant, the extension of PAP duration to 48-72 hours may be considered according to the type of transplant (ungraded good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Since PAP aims to achieve adequate tissue levels prior and during surgery to minimize SSIs, a single dose of preoperative PAP is recommended for most surgical procedures <ref type="bibr" target="#b4">[5]</ref>. In colonized patients, we either reported no clear evidence for changing the usual PAP (Table <ref type="table" target="#tab_1">1</ref>) or provided conditional recommendation to administer PAP regimens (that are already established according to international guidelines) according to the results of preoperative cultures (Table <ref type="table">3</ref>). Therefore, the duration of targeted PAP should align with current recommendations by the Infectious Diseases Society of America, American Society of Health-System Pharmacists, Surgical Infection Society, and Society for Healthcare Epidemiology of America (IDSA/ASHP/SIS/SHEA) as well as other international societies that consistently give indication for PAP discontinuation within 24 hours after surgery <ref type="bibr">[3,5,49e54]</ref>. No additional dosing is usually recommended for intravascular lines and devices, surgical drains, or stent placement <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b55">56]</ref>. The certainty of evidence supporting the benefits of limiting the duration of PAP to 24 hours is moderate mainly because of the high heterogeneity of studies performed in different types of surgery. The use of prolonged PAP (&gt;24-48 hours post-incision) has been associated with an increased risk of antibiotic resistance, acute kidney injury, and C. difficile infection in observational studies while conferring no apparent decrease in SSIs, as shown by a metaanalysis including only RCTs and by a recent cluster randomized trial in clean orthopaedic surgery <ref type="bibr">[57e60]</ref>. A meta-analysis on the optimal duration of antibiotic prophylaxis in cardiac surgery showed that PAP &gt;24 hours may be more efficacious in preventing sternal SSIs than shorter PAP, however the conclusions were hampered by the high heterogeneity and risk of bias of the included studies <ref type="bibr" target="#b60">[61]</ref>.</p><p>In transplant surgery there is currently no formal consensus on PAP duration due to a lack of comparative trials; recommendations based on expert opinion suggest the administration of PAP for 24 hours in kidney, 24-48 hours in liver, heart, pancreas, and for 48-72 hours in intestinal/multivisceral and lung transplantation <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b61">62]</ref>. Exceptions are represented by procedures that may require prolonged treatment (e.g. lung recipients with respiratory colonization or infection and intestinal or multivisceral transplant with infected mesh or fistulas) <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b61">62]</ref>.</p><p>Since the optimal duration of targeted PAP in MDR-GNB carriers should follow the same principles of PAP to minimize the risks associated with prolonged antibiotic administration, the recommendation is based on the abovementioned studies that do not specifically report the carrier status.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>Further research should be performed to investigate the clinical impact of shorter versus longer PAP in patients undergoing transplant surgery.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">Specific aspects of MDR-GNB carriage in SOT recipients</head><p>SOT recipients are exposed to MDR-GNB infections due to prolonged hospitalization, invasive procedures, ICU admission, and broad-spectrum antibiotic treatment <ref type="bibr" target="#b62">[63,</ref><ref type="bibr" target="#b63">64]</ref>. SSIs are a common issue and may occur in 3% to 53% of SOT recipients, with highest rates observed for intestinal, liver, and pancreas transplantation <ref type="bibr" target="#b61">[62]</ref>. LTR can develop intra-abdominal infections especially in the early post-LT period. In this group, the risk of ESCR-E and CRKP infections range from 6% to 13% and 3% and 10%, respectively, depending on the geographic area [65e67]. ESCR-E infections are common, accounting for up to 75% of MDR-GNB isolates in SOT recipients <ref type="bibr" target="#b66">[67]</ref>. Among nonfermenters, rates of CRAB and MDR PA up to 63% and 52%, respectively, were reported in bloodstream infections (BSIs) <ref type="bibr" target="#b65">[66,</ref><ref type="bibr" target="#b67">68,</ref><ref type="bibr" target="#b68">69]</ref>. Post-SOT infections caused by MDR-GNB are associated with higher mortality compared with their susceptible counterpart <ref type="bibr">[26,62,65,70e73]</ref>.</p><p>The American Society of Transplantation (AST) recommendations for MDR-GNB management and the Spanish Transplantation Infection Study Group (GESITRA) guidelines acknowledge that early detection of MDR-GNB carriers is useful to inform contact precaution in SOT candidates and may be taken into consideration when treating postoperative infections <ref type="bibr" target="#b44">[45,</ref><ref type="bibr" target="#b73">74]</ref>. Nevertheless, in asymptomatic SOT patients, non-outbreak settings, or in regions of endemicity the benefits of ESCR-E active surveillance are questioned <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b73">74]</ref>. New emerging evidence, however, showed increased rates of post-LT infections among ESCR-E, CRE, and CRAB carriers before SOT <ref type="bibr">[26,13,14,32e35]</ref>. Kidney transplant recipients (KTR) who were ESCR-E carriers had more frequently post-KT urinary tract infections (UTIs) versus noncarriers <ref type="bibr" target="#b74">[75]</ref>. Limited data are available for XDRPA colonization and occurrence of post-SOT infections. One prospective study in LTR showed that, out of 69 (38%) who were MDR-GNB carriers, 27% XDRPA carriers compared with 2% noncarriers developed postoperative XDRPA infections; however, most patients included in the study became colonized after LT <ref type="bibr" target="#b42">[43]</ref>. Colonization of non-GI sites, such as respiratory colonization by XDRPA in lung recipients, CRAB skin or multisite colonization in LT, or pretransplant bacteriuria in KTR may be relevant to target PAP, but data remain limited <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b75">76]</ref>.</p><p>PAP regimens and duration vary across transplant centres and are often customized to suit unique SSIs risks factors and surgical scenarios <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b76">77]</ref>. A worldwide survey involving lung transplant specialists reported that 67% of prescribers performed targeted PAP based on pretransplant MDR-GNB sputum colonization <ref type="bibr" target="#b75">[76]</ref>. The AST guidelines for SSIs prevention recommend different PAP according to the type of SOT (with broader coverage for intestinal/ multivisceral transplantation, lung transplantation, and delayed chest closure) and to adjust PAP in case of ongoing infections, with most recommendations being weak, with low quality evidence <ref type="bibr" target="#b17">[18]</ref>. Targeted PAP in ESCR-E or CRE SOT carriers remains undefined, and recipient screening is recommended for lung transplant <ref type="bibr" target="#b73">[74]</ref>. Although GESITRA recommended that ESCR-E colonized patients receive targeted PAP, no indication was given for a preferred regimen among beta-lactamase inhibitors, quinolones, aminoglycosides, or carbapenems <ref type="bibr" target="#b44">[45]</ref>. Ertapenem was mentioned as an acceptable alternative in selected ESCR-E carriers, with a recommendation to limit carbapenem-based PAP due to the risk of carbapenemases production. For CRE carriers, targeted PAP was not recommended except for centres reporting a high incidence of CRE SSIs, however a cut-off value was not provided <ref type="bibr" target="#b44">[45]</ref>. Data comparing PAP regimens in SOT remain scarce. A study including 819 KTR found a significant reduction in SSIs when amikacin was used in PAP instead of a cephalosporin <ref type="bibr" target="#b77">[78]</ref>. Although this result could be explained by the predominance of ESCR-E SSIs, data on preoperative carriage status were not provided <ref type="bibr" target="#b77">[78]</ref>. As previously reported, two recent retrospective studies with moderate and high risk of bias showed conflicting results on the benefit of targeted PAP in CRE carriers undergoing SOT <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b43">44]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations and future research</head><p>Recommendations for SOT recipients who are carriers of MDR-GNB before surgery are summarized in Table <ref type="table" target="#tab_1">1</ref>. Indications for future trials in ESCR-E, CRE, and CRAB carriers undergoing SOT are reported in the related sections. Moreover, future research is recommended for XDRPA screening to assess the risk of post-SOT infections among carriers. MDR-GNB multisite screening vs. rectal screening only should also be considered in SOT recipients before surgery to evaluate the impact on post-SOT infections according to the type of organ transplanted. Although these guidelines did not address postoperative colonization, the association between posttransplant MDR-GNB colonization and infections has often been documented, suggesting that culture surveillance should be considered also after SOT, according to the local epidemiology and individual risk factors <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b69">70,</ref><ref type="bibr" target="#b78">79]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Urologic surgery</head><p>Targeted PAP has been predominantly studied in transrectal ultrasound-guided prostate biopsy (TRUSPB) among fluoroquinolone-resistant (FQR)-E carriers due to the type of surgical approach (that involves entering the gastrointestinal tract) and the increased rates of FQR-E colonization reported before TRUSPB.</p><p>Question 7.1 Should patients be screened for FQR-E before TRUSPB?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>We suggest rectal screening to identify FQR-E carriers before TRUSPB (conditional recommendation, moderate certainty of evidence). Question 7.2 Should PAP be modified for patients colonized with FQR-E before TRUSPB?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>We suggest the use of targeted PAP for patients who are colonized with FQR-E before TRUSPB (conditional recommendation, moderate certainty of evidence).</p><p>Regimens that may be used for targeted PAP in FQR-E carriers are listed in Table <ref type="table">3</ref>.</p><p>Review of the evidence Fluoroquinolone-resistant (FQR)-E in TRUSPB. Infectious complications (e.g. UTIs, acute prostatitis, BSIs, sepsis) following TRUSPB occur in 1% to 5% of patients <ref type="bibr" target="#b79">[80,</ref><ref type="bibr" target="#b80">81]</ref>. FQ are broadly prescribed for PAP due to the IV/oral administration and the high penetration into prostate tissues <ref type="bibr" target="#b81">[82]</ref>. FQR-E rectal carriage has increased, showing rates exceeding 20% in certain areas, and was associated with alarming rates of post-TRUSPB infectious complications [83e87]. Bratzler et al. <ref type="bibr" target="#b4">[5]</ref> suggest that local resistance patterns to fluoroquinolones, particularly with E. coli, should be evaluated to help guiding PAP selection.</p><p>The retrieved studies reporting infectious complications and PAP in FQR-GNB carriers receiving TRUSPB are reported in Appendix S2. The use of ertapenem, cefoxitin, and fosfomycin in PAP was associated to reduced incidence of BSIs in FQR-E carriers undergoing TRUSPB <ref type="bibr" target="#b85">[86,</ref><ref type="bibr" target="#b87">88,</ref><ref type="bibr" target="#b88">89]</ref>. Data on TRUSPB PAP, however, are limited by a high variability in the regimens used and the short follow-up to assess infectious complications. Two single-centre observational studies performed in the US and Korea favoured targeted vs. routine PAP <ref type="bibr" target="#b89">[90,</ref><ref type="bibr" target="#b90">91]</ref>. Suwantarat et al. <ref type="bibr" target="#b89">[90]</ref> included 44 FQR-E. coli carriers (22% of screened patients); of these, 43% among those receiving an oral cephalosporin plus ciprofloxacin developed post-TRUSBP infections compared to none receiving targeted PAP (61% with cotrimoxazole). Dai et al. <ref type="bibr" target="#b90">[91]</ref> included 314 patients and 12% FQR-GNB carriers; of these, 36 (11%) received targeted PAP (69% cotrimoxazole, 56% in combination with intramuscular gentamicin) versus oral ciprofloxacin. Targeted PAP was associated with decreased odds of post-TRUSBP infections (OR 0.70; 95% CI 0.20-2.50). Bloomfield et al. <ref type="bibr" target="#b91">[92]</ref> used ertapenem-based PAP in 326 patients; of these, 6% and 9% were colonized with ESCR-E and FQR-E, respectively <ref type="bibr" target="#b91">[92]</ref>. Three (1%) episodes of post-TRUSPB sepsis were reported. Although we excluded single articles referring exclusively to ambulatory TRUSBP, data from comprehensive systematic review and meta-analyses were reviewed. Cussans et al. included nine observational studies and 4571 patients (23% colonized by FQR-GNB) comparing FQ-based with targeted PAP; post-TRUSPB infections were 4.6% versus 0.7%, respectively <ref type="bibr" target="#b92">[93]</ref>. The NNT to prevent one post-TRUSPB infection was 27. Scott et al. <ref type="bibr" target="#b93">[94]</ref> performed a meta-analysis of 15 articles up to March 2017 including two controlled trials and 13,320 patients. Post-TRUSPB infections were 3.4% versus 0.8% with an estimated risk difference of 2.6% for FQ-based versus targeted PAP. The NNT to prevent one post-TRUSPB infection was 39. No optimal targeted PAP for carriers was identified.</p><p>To date, the superiority of prolonged (e.g. 48-72 hours) or multiple-dose treatment versus short-course (24 hours) or singledose PAP has not been demonstrated <ref type="bibr" target="#b81">[82]</ref>. Some studies showed that PAP with 2 antibiotics caused the reduction of post-TRUSPB UTIs, but these results were not confirmed in clinical trials using targeted PAP <ref type="bibr" target="#b94">[95,</ref><ref type="bibr" target="#b95">96]</ref>. Other studies reported no benefits in the addition of aminoglycosides to FQ <ref type="bibr" target="#b96">[97,</ref><ref type="bibr" target="#b97">98]</ref>.</p><p>A recently published (therefore not formally included in the evidence review) randomized, non-blinded, multicenter trial including 1288 patients undergoing TRUSPB (15.8% FQR carriers) and comparing ciprofloxacin PAP versus culture-based PAP showed a risk reduction of -1.8% (95% CI -0.004 to 0.040) in the 7-day post-TRUSPB infection rate. FQR carriers had a 6.2-fold higher risk of early postbiopsy infection compared to noncarriers <ref type="bibr" target="#b98">[99]</ref>.</p><p>The European Association of Urology (EAU) guidelines pose a weak recommendation for the use of targeted PAP in TRUSPB, indicating fosfomycin trometamol, cephalosporin, and aminoglycoside as alternatives to FQ without addressing specific MDR-GNB [100]. The EAU strongly recommends considering the transperineal approach for prostate biopsy due to the lower risk of infectious complications. Furthermore, a recent RCT performed in Norway enrolling 792 patients performing transperineal prostate biopsy reported that PAP may be omitted in this population since infections were not significantly higher in patients receiving and not receiving PAP <ref type="bibr" target="#b100">[101]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>Further studies are recommended to understand the impact of colonization with MDR-GNB other than FQR-E on post-TRUSPB infections. High-quality trials are suggested to assess the efficacy of specific PAP regimens in FQR-E carriers undergoing TRUSPB. A recommendation for research is made to design trials of targeted PAP in ESCR-E carriers, especially in areas with increased ESCR-E burden. Future trials should include adequate monitoring of infectious complications and development of antibiotic resistance following surgery.</p><p>Other urologic surgery Question 7.3 Should screening be performed and PAP modified for patients colonized with MDR-GNB before urologic surgery?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head><p>Insufficient evidence is available at this time to recommend for or against screening to inform targeted PAP for patients who are colonized with MDR-GNB before urologic surgery (no recommendation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>There is limited evidence on the impact of targeted PAP on infectious complications following urologic surgery in MDR-GNB carriers. Rectal colonization may not be informative, while urinary cultures are often obtained to treat asymptomatic bacteriuria before surgery, as recommended by clinical practice guidelines <ref type="bibr" target="#b50">[51,</ref><ref type="bibr" target="#b101">102]</ref>. The 2019 American Urological Association (AUA) best practice guidelines report a high variability in prescribing PAP patterns for most urologic interventions <ref type="bibr" target="#b50">[51]</ref>. Although targeted PAP is not routinely recommended, the AUA guidelines suggest that, if PAP is required and a known history of MDR organisms is reported, an expanded antimicrobial coverage should be warranted <ref type="bibr" target="#b50">[51]</ref>. The EAU guidelines suggest that the identification of asymptomatic bacteriuria through urine culture before surgery aims to reduce the risk of infectious complications and to optimize antimicrobial coverage before invasive urological procedures, but do not provide recommendations on targeted PAP due to the high geographic variability in type of bacteria, susceptibility patterns, and availability of antibiotics [100].</p><p>Higher rates of postoperative infections were reported among patients with urinary colonization compared with noncolonized ones, and patients undergoing urologic surgery often have risk factors for MDR-GNB acquisition (e.g. previous surgical procedures, permanent bladder catheters, double J stents, etc.) <ref type="bibr" target="#b102">[103,</ref><ref type="bibr" target="#b103">104]</ref>. Nevertheless, studies comparing postoperative infections in MDR-GNB urinary carriers versus noncarriers are lacking. A small, prospective single-centre study included 75 patients undergoing urologic surgery and receiving PAP based on the results of urine cultures (from day 2 before surgery until withdrawal of bladder catheter or until day 7) <ref type="bibr" target="#b104">[105]</ref>. Sixteen (22%) ESCR-E carriers received targeted PAP mainly with aminoglycosides (63%), cefoxitin (19%), and imipenem (13%). Eleven (15%) postoperative infections, mainly SSIs, were detected in patients receiving targeted PAP compared with 5% in noncolonized ones (P¼ 0.028). A total of 31% ESCR-E carriers developed postoperative infections; 80% of these were caused by the same colonizing strain compared to 9% in noncarriers <ref type="bibr" target="#b104">[105]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research and conditional use in restricted trials</head><p>In urologic surgery other than TRUSBP, further research is needed to identify the impact of MDR-GNB colonization and targeted PAP based on preoperative cultures, including urinary cultures, on postoperative infections. Furthermore, the optimal targeted PAP for different MDR-GNB should be investigated according to the type of urological procedure and the local rates of antibiotic resistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations of the evidence and research needs</head><p>Our review has identified important knowledge gaps and limitations, including retrospective study designs, small sample sizes, lack of assessment of key outcomes, and a wide heterogeneity of surgical settings, types of PAP, and timing of assessment of postoperative infections from surgery. Most questions were addressed by observational studies with high risk of bias (Table <ref type="table" target="#tab_3">2</ref> and Tables <ref type="table" target="#tab_1">S1</ref> and<ref type="table" target="#tab_7">S2</ref>). Well-done RCTs are highly needed to fill in existing gaps and to improve patients' outcomes.</p><p>For ESCR-E and CRE carriers, increased evidence recently highlighted the association between rectal colonization and postoperative infections, supporting surveillance screening for MDR-GNB, especially in areas with high burden and for high-risk surgery, suggesting that targeted PAP may be effective in reducing SSIs. No RCTs, however, were performed comparing targeted with routine PAP in MDR-GNB carriers. Furthermore, routine prophylaxis may vary according to local protocols and different geographic areas, potentially impacting SSIs. One prospective multinational study showed a potential benefit for ertapenem use in ESCR-E carriers undergoing colorectal surgery <ref type="bibr" target="#b40">[41]</ref>. Previously, ertapenem-based PAP was used in studies not reporting colonization data, showing SSIs reduction in a retrospective study including 615 cancer patients undergoing abdominal surgery <ref type="bibr" target="#b105">[106]</ref>, while a RCT including 499 patients undergoing elective colorectal surgery reported similar efficacy for ertapenem versus routine PAP <ref type="bibr" target="#b106">[107]</ref>. Because of the limited options currently available to effectively treat MDR-GNB, welldesigned studies exploring optimal PAP are needed. These trials should investigate the impact of targeted PAP on microbiological, epidemiological, and clinical outcomes as well as development of resistance to the antibiotics used for targeted regimens. Antibiotic type and dosing should be chosen according to PK/PD principles and considering the cost-effectiveness of the intervention. Few studies have explored the impact of carrier status for MDR-GNB other than ESCR-E, CRE, and CRAB. XDRPA as well as PDR-GNB colonization effects on SSIs need further attention, as colonization rates by these bacteria are likely to increase in the future. If PAP including antibiotic combinations (e.g. two or more antibiotics with in vitro efficacy against MDR-GNB) are investigated, efforts should be made to analyse their potential for resistance selection and side effects.</p><p>Other antibiotic-based interventions for reducing postsurgical infections (e.g. decolonization, SDD) and targeting MDR-GNB carriers before surgery have not been explored in clinical trials. The ENTHERE study group performed an open-label, multicenter RCT treating 53 SOT recipients who were MDR-GNB carriers with oral colistin plus neomycin, while 52 did not receive the decontamination protocol. No significant difference in infections due to MDR Enterobacterales was observed between groups, however patients enrolled were colonized not only before (58%) but also after SOT (42%) <ref type="bibr" target="#b107">[108]</ref>. SDD with oral colistin, tobramycin, and amphotericin B was performed in a RCT in colorectal surgery showing a reduction of postoperative infections in the SDD arm compared to controls, nevertheless carrier status was not tested <ref type="bibr" target="#b108">[109]</ref>. Since recent trials in colorectal surgery showed that the use of oral antibiotics (with or without mechanical bowel preparation) may reduce the risk of SSIs, protocols exploring the use of oral therapy with activity on MDR-GNB should be considered <ref type="bibr" target="#b109">[110,</ref><ref type="bibr" target="#b110">111]</ref>. While coordinated actions (e.g. decolonization, active surveillance, and stewardship measures) seemed to contribute to SSIs reduction for MDR Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus, no bundles complementing PAP in MDR-GNB carriers undergoing surgery were found <ref type="bibr" target="#b111">[112]</ref>. Metagenomic studies assessing the effect of antibiotic treatment on the microbiota composition and on patients' colonization dynamics over time should be investigated within new protocols or bundled interventions targeting MDR-GNB.</p><p>The reduction of SSIs requires a comprehensive approach in terms of antibiotic-based interventions and best surgical practices (e.g. minimization of surgical operative time, regulation of glucose and temperature, optimization of sterile techniques, and management of patient comorbidities) <ref type="bibr" target="#b48">[49,</ref><ref type="bibr" target="#b58">59,</ref><ref type="bibr" target="#b112">113]</ref>. The optimization of antibiotic-based interventions should focus not only on targeted PAP but also on heightening stewardship initiatives to monitor and contain the consequences of new prescription patterns, enhance surveillance protocols, improve local adherence to guidelines, and promote a multidisciplinary approach to target SSIs <ref type="bibr" target="#b113">[114]</ref>.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head/><label/><figDesc>Righi, Clin Microbiol Infect 2023;29:463 © 2022 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious</figDesc><table/></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>Summary of recommendations</figDesc><table><row><cell>Recommendation</cell></row></table><note><p><p><p><p><p><p>Carbapenem-resistant Acinetobacter baumannii (CRAB) Recommendation on screening for CRAB colonization</p>We conditionally recommend implementing rectal screening to identify CRAB carriers before liver transplant surgery according to the local epidemiology</p>Conditional Low</p>It might be good clinical practice to screen, according to the local epidemiology, all solid organ transplant recipients for CRAB before surgery</p>Ungraded good practice statement Expert opinion</p>Recommendation on targeted PAP for patients who are colonized with CRAB before surgery There is insufficient evidence for or against targeted PAP for patients who are colonized with CRAB before surgery at the time of writing and therefore no recommendation can be issued CRAB, carbapenem-resistant A. baumannii; CRE, carbapenem-resistant Enterobacterales; ESCR-E; extended-spectrum cephalosporin-resistant Enterobacterales; FQR-E, fluoroquinolone-resistant Enterobacterales; MDR-GNB, multidrug-resistant Gram-negative bacteria; PAP, perioperative antibiotic prophylaxis; TRUSPB, transrectal ultrasoundguided prostate biopsy.</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc>Characteristics of studies comparing postsurgical infectious complications in MDR-GNB carriers versus noncarriers</figDesc><table><row><cell>Author, year</cell><cell>Type of study</cell><cell>Country</cell><cell>Study period Type of</cell><cell>Target</cell><cell>Carrier %</cell><cell>Time between</cell><cell>Prophylaxis used</cell><cell>Postoperative infections (%);</cell></row><row><cell/><cell/><cell/><cell>surgery</cell><cell>bacteria</cell><cell>(screened</cell><cell>sampling and</cell><cell/><cell>postsurgical follow-up time</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell>patients)</cell><cell>surgery</cell><cell/><cell/></row><row><cell>Bert, 2012 a [26]</cell><cell>Prospective cohort study</cell><cell>France</cell><cell>2001 e 2010 LT</cell><cell>ESCR-E</cell><cell>4 (710)</cell><cell cols="2">On the day of LT Cefoxitin</cell><cell>13/29 (45) carriers vs. 26/681 (4) noncarriers</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>(P &lt; 0.0001); 120 d</cell></row><row><cell>Bert, 2014 a [27]</cell><cell>Prospective cohort study</cell><cell>France</cell><cell>2009 e 2011 LT</cell><cell>ESCR-E</cell><cell cols="3">16 (317) On the day of LT Cefoxitin</cell><cell>24/50 (48) carriers vs. 18/267 (7) noncarriers</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>(P &lt; 0.001); 120 d</cell></row><row><cell cols="2">Golzarri, 2019 [28] Prospective cohort study</cell><cell>Mexico</cell><cell cols="2">2014 e 2015 GI and GYN ESCR-E</cell><cell cols="2">18 (171) On the day of</cell><cell>Cefuroxime (23%),</cell><cell>SSIs: 10/37 (27) carriers (results include</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>admission</cell><cell>metronidazole (12%),</cell><cell>also seven postsurgical carriers) vs.15/34</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>ceftriaxone (10%),</cell><cell>(11) noncarriers (P ¼ 0.016); ESCR-E SSIs</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>ciprofloxacin (5%),</cell><cell>11% carriers vs. 4% noncarriers; 30 d</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>clindamycin (4%),</cell><cell/></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>cephalothin (1%)</cell><cell/></row><row><cell>Dubinsky-Pertzov,</cell><cell>Prospective cohort study</cell><cell>Israel,</cell><cell>2012 e 2017 Colorectal</cell><cell>ESCR-E</cell><cell cols="2">14 (3600) 14 days to 1 hour</cell><cell>Cephalosporin þ</cell><cell>SSIs: 55/220 (25) carriers vs. 49/440 (11)</cell></row><row><cell>2019 [29]</cell><cell/><cell>Switzerland</cell><cell/><cell/><cell/><cell>prior to surgery</cell><cell>metronidazole</cell><cell>noncarriers, P &lt; 0.001; ESCR-E SSIs 7%</cell></row><row><cell/><cell/><cell>Serbia</cell><cell/><cell/><cell/><cell/><cell/><cell>carriers vs. 2% noncarriers; 30 d</cell></row><row><cell>Apisarnthanarak,</cell><cell>Prospective cohort study</cell><cell>Thailand</cell><cell cols="2">2017 e 2019 Abdominal ESCR-E</cell><cell cols="2">36 (360) Within 1 day</cell><cell>2G Ceph (48%),</cell><cell>SSIs: 40/129 (31) carriers vs. 11/231</cell></row><row><cell>2019 b [30]</cell><cell/><cell/><cell/><cell/><cell/><cell>before surgery</cell><cell>3G Ceph (25%),</cell><cell>noncarriers (5); ESCR-E SSIs 6% carriers</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>BLBLI (14%), carbapenems (12%)</cell><cell>vs. 0% noncarriers; 28 d</cell></row><row><cell>De Pastena,</cell><cell>Prospective, nonrandomized</cell><cell>Italy</cell><cell cols="2">2015 e 2018 Pancreatic ESCR-E</cell><cell cols="2">11 (679) Within 3 weeks</cell><cell>Ampicillin/sulbactam (56%),</cell><cell>41/76 (54) carriers vs. 221/603 (37)</cell></row><row><cell>2021 [31]</cell><cell>interventional study</cell><cell/><cell/><cell/><cell/><cell>prior to surgery</cell><cell>piperacillin/tazobactam (44%)</cell><cell>noncarriers;</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>SSIs: 32/76 (42) vs. 171/603 (28); NA</cell></row><row><cell>Logre, 2021 [32]</cell><cell>Retrospective cohort study</cell><cell>France</cell><cell>2010 e 2016 LT</cell><cell>ESCR-E</cell><cell cols="2">13 (749) During follow-up</cell><cell>ESCR inactive (16%) and active</cell><cell/></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>before LT (NA)</cell><cell>(84%: cefoxitin 40%,</cell><cell/></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>and at the time of</cell><cell>carbapenem 31%, piperacillin/</cell><cell/></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>transplant</cell><cell>tazobactam 29%)</cell><cell/></row><row><cell cols="2">Giannella, 2015 [33] Prospective cohort study</cell><cell>Italy</cell><cell>2010 e 2013 LT</cell><cell cols="2">CRE (CRKP) 4 (237)</cell><cell>Multiple times</cell><cell>Ampicillin/sulbactam</cell><cell>CRKP infections: 18% carriers vs.</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>before LT c</cell><cell/><cell>2% noncarriers (P &lt; 0.001);</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>180 d</cell></row><row><cell>Mazza, 2017 [12]</cell><cell>Retrospective cohort study</cell><cell>Italy</cell><cell>2012 e 2015 LT</cell><cell cols="2">CRE (CRKP) 3 (310)</cell><cell cols="2">On the day of LT Ampicillin/sulbactam</cell><cell>CRKP infections: 3/10 (30) carriers</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>vs. none in noncarriers</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>(5/10 in post-LT carriers); ND</cell></row><row><cell cols="2">Giannella, 2019 [34] Prospective cohort study</cell><cell>Italy</cell><cell>2010 e 2017 LT</cell><cell cols="2">CRE (CRKP) 7 (553)</cell><cell>Multiple times</cell><cell>Ampicillin/sulbactam</cell><cell>CRKP infections: 14/38 carriers (37)</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell>before LT d</cell><cell/><cell>vs. 6/406 (2) noncarriers;</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>1 year</cell></row><row><cell>Freire, 2021 [13]</cell><cell>Retrospective cohort study</cell><cell>Brazil</cell><cell>2010 e 2018 LT</cell><cell>CRE</cell><cell>13 (762)</cell><cell>On admission</cell><cell>Ampicillin þ cefotaxime (61%),</cell><cell>CRE SSIs: 22/98 (22) carriers vs.</cell></row><row><cell/><cell/><cell/><cell/><cell>CRAB</cell><cell>4 (762)</cell><cell>for LT</cell><cell>ampicillin þ amikacin (39%)</cell><cell>5% noncarriers, P ¼ 0.001; 30 d</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>CRAB SSIs: 8/28 (29) carriers vs. 3%</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>noncarriers, P ¼ 0.001; 30 d</cell></row><row><cell>Freire, 2016 [35]</cell><cell>Prospective cohort study</cell><cell>Brazil</cell><cell>2009 e 2011 LT</cell><cell>CRAB</cell><cell cols="3">12 (196) On the day of LT Ampicillin þ cefotaxime;</cell><cell>CRAB infections: 11/24 (46)</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>4 (16%) added polymyxin</cell><cell>carriers vs. 45/172 (26) noncarriers;</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>(carriers: 20% CRAB vs. 8% nonCRAB</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>infections, P ¼ 0.002);</cell></row><row><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell/><cell>120 d</cell></row></table><note><p><p><p>ESCR-E infections 45/100</p><ref type="bibr" target="#b44">(45)</ref> </p>carriers (39% same ESCR-E strain) vs. 23/649 (4) noncarriers; 30 and 90 d 2G Ceph, second generation cephalosporins; 3G Ceph, third generation cephalosporins; CRAB, carbapenem-resistant A. baumannii; CRE, carbapenem-resistant Enterobacterales ; CRKP, carbapenem-resistant K. pneumoniae; d, days; ESCR-E, extended-spectrum cephalosporin-resistant Enterobacterales; GI, gastrointestinal; GYN, gynecological; LT, liver transplant; NA, not available. If not reported as SSIs (surgical site infections), infections are intended as any postoperative infection. Risk of bias is reported in Supplementary Material (Appendix 2). Sampling was performed by rectal swab (RS) for all studies except Freire 2016 (also throat and axilla swabs obtained). a Bert 2012 and 2014: partial data overlap possible during 01/2009-04/2010. b Apisarnthanarak included swabs until day 5 after surgery. c Giannella 2015: RS performed monthly while on a waiting list; colonization detected from day 40 until transplant day. d Giannella 2019: RS positivity at a median time of 12 d pre-LT (IQR 0.75-40).</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head/><label/><figDesc>. Righi et al. / Clinical Microbiology and Infection 29 (2023) 463e479 ESCR-E carriers among 360 patients undergoing abdominal surgery receiving various PAP, reporting ESCR-E colonization as a risk factor for SSIs (adjusted OR [aOR] 2.40, 95% CI 1.19-19.91); all ESCR-E SSIs occurred in ESCR-E carriers. Among LTR, Bert et al. [26] reported increased rates of ESCR-E colonization over time (from 0% in 2001e2003 to 11% in 2009e2010 in LTR). Logre et al. [32] enrolled 100 colonized LTR, reporting a sensitivity of 0.62 and a specificity 0.91 for pre-LT ESCR-E rectal carriage in predicting post-LT ESCR-E infections. Compared with other Enterobacterales, ESCR-K. pneumoniae carrier status was an independent predictor of ESCR-E infection.The studies retrieved, involving mainly abdominal and liver transplant surgery, showed moderate or high risk of bias (only one multicentric study in colorectal surgery had low risk of bias) and reported an increased rate of postoperative infections and SSIs in ESCR-E carriers compared with noncarriers, suggesting that screening for carriers would define a population at risk that may be benefit of interventions to reduce postoperative infections.</figDesc><table><row><cell>Question 1.2: Should PAP be adapted in patients colonized with</cell></row><row><cell>ESCR-E before surgery?</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2</head><label>2</label><figDesc/><table><row><cell>with infection (OR 10.76, 95% CI 2.60e44) but was detected only</cell></row><row><cell>by univariable analysis. Giannella et al. [33] performed a pro-</cell></row><row><cell>spective, single-centre study analysing 237 LTR and 10 (4%) CRKP</cell></row><row><cell>carriers, showing lower rates of post-LT infections in non-</cell></row><row><cell>colonized versus CRKP colonized within 120 days after LT (2%</cell></row><row><cell>versus 18% respectively, P &lt; 0.001) [33]. The same transplant</cell></row><row><cell>centre included 553 LTR between 2010 and 2017 showing that</cell></row><row><cell>CRE colonization increased significantly over time (RR 1.21, 95%</cell></row><row><cell>CI 1.05e1.39) [34]. Multivariable analysis identified CRE coloni-</cell></row><row><cell>zation before transplantation as an independent risk for CRE</cell></row><row><cell>infection (HR 18.50, 95% CI 6.76e50.54). Freire et al. reported 72</cell></row><row><cell>(40%) CRKP carriers among 181 LTR; 42% became CRKP infected</cell></row><row><cell>compared with one out of 139 noncarriers [43]. CRKP carriers</cell></row><row><cell>were more likely to develop an infection caused by CRKP</cell></row><row><cell>compared with those who were colonized by other MDR-GNB</cell></row><row><cell>(RR 1.28; 95% CI 1.04-1.58). The study, however, combined pre-</cell></row><row><cell>and post-transplant colonization. The same authors performed a</cell></row><row><cell>study enrolling 98 (13%) LTR who were CRE carriers, showing</cell></row><row><cell>higher rates of CRE SSIs in carriers versus noncarriers (P¼ 0.001)</cell></row><row><cell>[13]. CRE acquisition before transplantation was identified as an</cell></row><row><cell>independent risk factor for SSIs caused by any type of bacteria</cell></row><row><cell>(OR 2.32, 95% CI 1.43-3.77) and by MDR-GNB (OR 3.17, 95% CI</cell></row><row><cell>1.46-6.89). Although these studies highlight an increased rate of</cell></row><row><cell>postoperative infections among CRE carriers vs. noncarriers,</cell></row><row><cell>several limitations were detected, including the study design (all</cell></row><row><cell>observational single-site studies, retrospective in two cases) and</cell></row><row><cell>the variable, or not reported, follow-up time for infection</cell></row><row><cell>detection (Table 2).</cell></row></table><note><p><p><p><p><p>)</p><ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b33">34]</ref></p>. Mazza et al.</p><ref type="bibr" target="#b11">[12]</ref> </p>identified 10 out of 310 (3%) patients who CRKP carriers before LT; 30% developed CRKP infections documented up to 70 days post-LT with a mortality of 100%. Pretransplant colonization was significantly associated Question 2.2: Should PAP be adapted in patients colonized with CRE before surgery?</p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>The authors thank <rs type="person">Dr. Luigia Scudeller</rs> for the support in the preparation of the guideline and literature review, <rs type="person">Dr. Benedikt Huttner</rs> and <rs type="person">Dr. Effrossyni Gkrania -Klotsas</rs> for supervising the process, and the CMI reviewers and commentators of the <rs type="institution">ESCMID</rs> open consultation for their contribution to the quality of these guidelines.</p></div>
			</div>			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Author contributions E.R. wrote the study protocol, supervised the work of the panel, selected and voted for PICO questions and for other relevant decision, performed literature search, drafted and approved the manuscript. N.T.M. wrote the study protocol, selected and voted for PICO questions and for other relevant decision, performed literature search, critically revised and approved the manuscript. X.G., M.D.T., C.E., A.W.F., M.G., J.K., E.P., G.S., C.T. selected and voted for PICO questions and for other relevant decisions, reviewed the literature, critically revised and approved the manuscript. E.LA.C, E.C., A.V., voted for PICO questions, performed literature search and data extraction, and approved the manuscript. E.T. chaired the panel, supervised the work of the panel, selected and voted for PICO questions and for other relevant decisions, drafted and approved the manuscript. E.R. and N.T.M. made equal contributions to these guidelines.</p><p>Transparency declaration E.R., N.T.M, M.D.T., J.K., E.P., A.W.F., E.L.A.C, A.V., G.S., C.E., C.T., E.T.: nothing to disclose. X.G. reports receiving a grant from 3M, consulting fees from Pfizer, and speaker fee from Pfizer, Johnson &amp; Johnson/Ethicon, MSD, and AstraZeneca; M.G. reports speaker fees from MSD, Shionogi, and Pfizer; E.C. reports speaker fees from Pfizer and Gilead.</p><p>These guidelines were supported by ESCMID.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Updating</head><p>The guidelines will be updated according to ESCMID recommendations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p>Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.12.012.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tacconelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Carrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Savoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mendelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Monnet</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(17)30753-3</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(17)30753-3"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="318" to="e327"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Surgical site infections: epidemiology, microbiology and prevention</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stoessel</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0195-6701(08)60017-1</idno>
		<ptr target="https://doi.org/10.1016/S0195-6701(08)60017-1"/>
	</analytic>
	<monogr>
		<title level="j">J Hosp Infect</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="3" to="e10"/>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m">Global guidelines for the prevention of surgical site infection</title>
		<meeting><address><addrLine>Geneva</addrLine></address></meeting>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Kirkland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Trivette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Sexton</surname></persName>
		</author>
		<idno type="DOI">10.1086/501572</idno>
		<ptr target="https://doi.org/10.1086/501572"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="725" to="e730"/>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Clinical practice guidelines for antimicrobial prophylaxis in surgery</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bratzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Dellinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Olsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Perl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Auwaerter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Bolon</surname></persName>
		</author>
		<idno type="DOI">10.1089/sur.2013.9999</idno>
		<ptr target="https://doi.org/10.1089/sur.2013.9999"/>
	</analytic>
	<monogr>
		<title level="j">Surg Infect (Larchmt)</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="73" to="e156"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Teillant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laxminarayan</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(15)00270-4</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(15)00270-4"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1429" to="e1437"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Is the efficacy of antibiotic prophylaxis for surgical procedures decreasing? Systematic review and meta-analysis of randomized control trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Trett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alvarez-Uria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laxminarayan</surname></persName>
		</author>
		<idno type="DOI">10.1017/ice.2018.295</idno>
		<ptr target="https://doi.org/10.1017/ice.2018.295"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="133" to="e141"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huprikar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Factor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Calfee</surname></persName>
		</author>
		<idno type="DOI">10.1086/592412</idno>
		<ptr target="https://doi.org/10.1086/592412"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1099" to="e106"/>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Management of superficial and deep surgical site infection: an international multidisciplinary consensus</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sganga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baguneid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dohmen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Giamarellos-Bourboulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Romanini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vozikis</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13304-021-01029-z</idno>
		<ptr target="https://doi.org/10.1007/s13304-021-01029-z"/>
	</analytic>
	<monogr>
		<title level="j">Updates Surg</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1315" to="e1325"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Surgical site infections -review of current knowledge, methods of prevention</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kolasi</surname></persName>
		</author>
		<idno type="DOI">10.5604/01.3001.0012.7253</idno>
		<ptr target="https://doi.org/10.5604/01.3001.0012.7253"/>
	</analytic>
	<monogr>
		<title level="j">Pol Przegl Chir</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="41" to="e47"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Association between rectal colonization with highly resistant Gram-negative rods (HR-GNRs) and subsequent infection with HR-GNRs in clinical patients: a one year historical cohort study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Souverein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Euser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Herpers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kluytmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jwa</forename><surname>Rossen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Den</forename><surname>Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0211016</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0211016"/>
	</analytic>
	<monogr>
		<title level="j">PLOS ONE</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">211016</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Carbapenem-resistant Klebsiella pneumoniae infections early after liver transplantation: a single-center experience</title>
		<author>
			<persName><forename type="first">E</forename><surname>Mazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Prosperi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Panzeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Limuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nichelatti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Gasperi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.transproceed.2017.02.028</idno>
		<ptr target="https://doi.org/10.1016/j.transproceed.2017.02.028"/>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="677" to="e81"/>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Surgical site infection after liver transplantation in the era of multidrug-resistant bacteria: what new risks should be considered?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Atw</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Icv</forename><surname>Oshiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Andraus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'albuquerque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lac</forename><surname>Abdala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.diagmicrobio.2020.115220</idno>
		<ptr target="https://doi.org/10.1016/j.diagmicrobio.2020.115220"/>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page">115220</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Colonisation with extended-spectrum beta-lactamase-producing Enterobacterales and infection risk in patients undergoing surgery: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Righi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Scudeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Visentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Mutters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meroi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schwabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">32nd Eur congress of clinical microbiology and infectious diseases (ECCMID)</title>
		<meeting><address><addrLine>Lisbon</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tacconelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mazzaferri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>De Smet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bragantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Eggimann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Huttner</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2019.01.005</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2019.01.005"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="807" to="e817"/>
			<date type="published" when="2019-07">2019 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m">Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis</title>
		<imprint>
			<publisher>European Center for Disease Prevention and Control</publisher>
			<date type="published" when="2013">2013</date>
		</imprint>
		<respStmt>
			<orgName>European Centre for Disease Prevention and Control</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Stockholm</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Berríos-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Umscheid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bratzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Leas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Kelz</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamasurg.2017.0904</idno>
		<ptr target="https://doi.org/10.1001/jamasurg.2017.0904"/>
	</analytic>
	<monogr>
		<title level="j">JAMA Surg</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="784" to="e91"/>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Community of Practice. Surgical site infections: guidelines from the American society of transplantation infectious diseases community of practice</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Abbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Grossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ast</forename><surname>Id</surname></persName>
		</author>
		<idno type="DOI">10.1111/ctr.13589</idno>
		<ptr target="https://doi.org/10.1111/ctr.13589"/>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">13589</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Carbapenems for surgical prophylaxis?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Sexton</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMe068258</idno>
		<ptr target="https://doi.org/10.1056/NEJMe068258"/>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="2693" to="e2695"/>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</title>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jclinepi.2009.06.005</idno>
		<ptr target="https://doi.org/10.1016/j.jclinepi.2009.06.005"/>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1006" to="e1012"/>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Magiorakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Srinivasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Falagas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Giske</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1469-0691.2011.03570.x</idno>
		<ptr target="https://doi.org/10.1111/j.1469-0691.2011.03570.x"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="268" to="e81"/>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<ptr target="from:epoc.cochrane.org/resources/epoc-resourcesreview-authors"/>
		<title level="m">Cochrane Effective Practice Organisation of Care</title>
		<imprint>
			<publisher>EPOC Resources for review authors</publisher>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Newcastle-Ottawa quality assessment scale cohort studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Losos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
		<respStmt>
			<orgName>University of Ottawa</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">GRADE handbook for grading quality of evidence and strength of recommendations</title>
		<author>
			<persName><forename type="first">Hbj</forename><surname>Schu€nemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grade Working</forename><surname>The</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<ptr target="guidelinedevelopment.org/handbook"/>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Alonso-Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schünemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Djulbegovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nothacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lange</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jclinepi.2016.07.006</idno>
		<ptr target="https://doi.org/10.1016/j.jclinepi.2016.07.006"/>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="3" to="e7"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pretransplant fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and infection after liver transplant</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Larroque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Paugam-Burtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dondero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Durand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marcon</surname></persName>
		</author>
		<idno type="DOI">10.3201/eid1806.110139</idno>
		<ptr target="https://doi.org/10.3201/eid1806.110139"/>
	</analytic>
	<monogr>
		<title level="j">France Emerg Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="908" to="e916"/>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Risk factors associated with preoperative fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in liver transplant recipients</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Larroque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dondero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Durand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Paugam-Burtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Belghiti</surname></persName>
		</author>
		<idno type="DOI">10.1111/tid.12169</idno>
		<ptr target="https://doi.org/10.1111/tid.12169"/>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="84" to="e89"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Colonization by fecal extendedspectrum beta-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Golzarri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Silva-S</forename><surname>Anchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Cornejo-Ju</forename><surname>Arez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barrios-Camacho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Chora-Hern Andez</forename><surname>Ld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vel Azquez-Acosta</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajic.2019.01.020</idno>
		<ptr target="https://doi.org/10.1016/j.ajic.2019.01.020"/>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="916" to="e921"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dubinsky-Pertzov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fankhauser-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Radovanovic</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciy768</idno>
		<ptr target="https://doi.org/10.1093/cid/ciy768"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1699" to="e704"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Outcomes of extended-spectrum beta-lactamases producing Enterobacteriaceae colonization among patients abdominal surgery patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Apisarnthanarak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mingmalairak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mahawongkajit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Juntong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Limpavitayaporn</surname></persName>
		</author>
		<idno type="DOI">10.1017/ice.2019.254</idno>
		<ptr target="https://doi.org/10.1017/ice.2019.254"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1290" to="e1293"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis with piperacillin-tazobactam reduces postoperative infectious complication after pancreatic surgery: an interventional, non-randomized study</title>
		<author>
			<persName><forename type="first">M</forename><surname>De Pastena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Paiella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Azzini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zaffagnini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Scarlini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Montagnini</surname></persName>
		</author>
		<idno type="DOI">10.1089/sur.2020.260</idno>
		<ptr target="https://doi.org/10.1089/sur.2020.260"/>
	</analytic>
	<monogr>
		<title level="j">Surg Infect (Larchmt)</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="536" to="e542"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Risk factors and impact of perioperative prophylaxis on the risk of extendedspectrum beta-lactamase-producing Enterobacteriaceae-related infection among carriers following liver transplantation</title>
		<author>
			<persName><forename type="first">E</forename><surname>Logre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Khoy-Ear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Janny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giabicani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Grigoresco</surname></persName>
		</author>
		<idno type="DOI">10.1097/TP.0000000000003231</idno>
		<ptr target="https://doi.org/10.1097/TP.0000000000003231"/>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="338" to="e345"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre-and posttransplant colonization</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bartoletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Morelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tedeschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cristini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tumietto</surname></persName>
		</author>
		<idno type="DOI">10.1111/ajt.13136</idno>
		<ptr target="https://doi.org/10.1111/ajt.13136"/>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1708" to="e1715"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bartoletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Campoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Coladonato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pascale</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2019.04.014</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2019.04.014"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1525" to="e1531"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Carbapenem-resistant Acinetobacter baumannii acquired before liver transplantation: impact on recipient outcomes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Pierrotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Oshiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Bonazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Machado</surname></persName>
		</author>
		<idno type="DOI">10.1002/lt.24389</idno>
		<ptr target="https://doi.org/10.1002/lt.24389"/>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="615" to="e626"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Auzin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tacconelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodríguez-Baño</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hulscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Adang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2021.12.003</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2021.12.003"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="928" to="e935"/>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: Practical and conceptual aspects</title>
		<author>
			<persName><forename type="first">E</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Margalit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dkaa496</idno>
		<ptr target="https://doi.org/10.1093/jac/dkaa496"/>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="40" to="e46"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Classifying antibiotics in the WHO essential Medicines list for optimal use-be AWaRe</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sharland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pulcini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathur</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(17)30724-7</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(17)30724-7"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="18" to="e20"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<ptr target="https://www.who.int/publications/i/item/2021-aware-classification"/>
		<title level="m">WHO 2021 AWaRe classification. WHO access, watch, reserve, classification of antibiotics for evaluation and monitoring of use</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Carrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Retamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>T€ Angd En</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bitterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2021.11.025</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2021.11.025"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="521" to="e547"/>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Personalized ertapenem prophylaxis for carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae undergoing colorectal surgery</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fankhauser-Rodriguez</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciz524</idno>
		<ptr target="https://doi.org/10.1093/cid/ciz524"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1891" to="e1897"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generationcephalosporin-resistant Enterobacterales after colorectal surgery</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lellouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Frenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2021.02.002</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2021.02.002"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1481" to="e1487"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Surveillance culture for multidrug-resistant gram-negative bacteria: Performance in liver transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Villela</forename><surname>Soares Oshiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Bonazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Pierrotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ajic.2016.12.010</idno>
		<ptr target="https://doi.org/10.1016/j.ajic.2016.12.010"/>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="40" to="e44"/>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Taimur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pouch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zubizarreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mazumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rana</forename><forename type="middle">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1111/ctr.14239</idno>
		<ptr target="https://doi.org/10.1111/ctr.14239"/>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page">14239</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Aguado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fern</forename><surname>Andez-Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cordero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fortún</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gudiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.trre.2017.07.001</idno>
		<ptr target="https://doi.org/10.1016/j.trre.2017.07.001"/>
	</analytic>
	<monogr>
		<title level="j">Transplant Rev (Orlando)</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="36" to="e57"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Detecting carbapenem-resistant Acinetobacter baumannii (CRAB) carriage: which body site should be cultured?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lellouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ben</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
		<idno type="DOI">10.1017/ice.2020.197</idno>
		<ptr target="https://doi.org/10.1017/ice.2020.197"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="965" to="e967"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Duration of colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae after hospital discharge</title>
		<author>
			<persName><forename type="first">G</forename><surname>Birgand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Armand</forename><forename type="middle">-</forename><surname>Lefevre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lolom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ruppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Andremont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lucet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ajic.2012.05.015</idno>
		<ptr target="https://doi.org/10.1016/j.ajic.2012.05.015"/>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="443" to="e447"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Genomic surveillance reveals diversity of multidrugresistant organism colonization and infection: a prospective cohort study in liver transplant recipients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Macesic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gomez-Simmonds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Giddins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Ferguson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Korakavi</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciy199</idno>
		<ptr target="https://doi.org/10.1093/cid/ciy199"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="905" to="e912"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Strategies to prevent surgical site infections in acute care hospitals: 2014 update</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Podgorny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Berrios-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bratzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Dellinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Greene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="66" to="e88"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Prevention and treatment of surgical site infection: Summary of NICE guidance</title>
		<author>
			<persName><forename type="first">D</forename><surname>Leaper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burman-Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Worster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gautam-Aitken</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.a1924</idno>
		<ptr target="https://doi.org/10.1136/bmj.a1924"/>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">337</biblScope>
			<date type="published" when="1924">2008. 1924</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Best practice statement on urologic procedures and antimicrobial prophylaxis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lightner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wymer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kavoussi</surname></persName>
		</author>
		<idno type="DOI">10.1097/JU.0000000000000509</idno>
		<ptr target="https://doi.org/10.1097/JU.0000000000000509"/>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="351" to="e356"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis in surgery</title>
	</analytic>
	<monogr>
		<title level="m">Scottish Intercollegiate Guidelines Network (SIGN)</title>
		<meeting><address><addrLine>Edinburgh: SIGN</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Preventing surgical site infectionskey recommendations for practice</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
		<respStmt>
			<orgName>Royal College of Physicians of Ireland</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<title level="m" type="main">bundle to prevent surgical site infection</title>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Health UDo. UK Department of Health Care</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Evidence-based update to the U.S. Centers for disease control and prevention and healthcare infection control practices advisory Committee guideline for the prevention of surgical site infection: Developmental process</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Berríos-Torres</surname></persName>
		</author>
		<idno type="DOI">10.1089/sur.2015.264</idno>
		<ptr target="https://doi.org/10.1089/sur.2015.264"/>
	</analytic>
	<monogr>
		<title level="j">Surg Infect (Larchmt)</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="256" to="e61"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Timing of surgical antibiotic prophylaxis and the risk of surgical site infection</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Hawn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Richman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Vick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Deierhoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Henderson</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamasurg.2013.134</idno>
		<ptr target="https://doi.org/10.1001/jamasurg.2013.134"/>
	</analytic>
	<monogr>
		<title level="j">JAMA Surg</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="649" to="e57"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Samore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lichtenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamasurg.2019.0569</idno>
		<ptr target="https://doi.org/10.1001/jamasurg.2019.0569"/>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="2916" to="e2921"/>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Association of duration and type of surgical prophylaxis with antimicrobialassociated adverse events</title>
		<author>
			<persName><forename type="first">W</forename><surname>Branch-Elliman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Strymish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Itani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<idno type="DOI">10.1001/jamasurg.2019.0569</idno>
		<ptr target="https://doi.org/10.1001/jamasurg.2019.0569"/>
	</analytic>
	<monogr>
		<title level="j">JAMA Surg</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="590" to="e598"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>De Jonge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Qjj</forename><surname>Boldingh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Dellinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salanti</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(20)30084-0</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(20)30084-0"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1182" to="1e92"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Effect of antimicrobial prophylaxis duration on health care-associated infections after clean orthopedic surgery: a cluster randomized trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shinozaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tokimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tajiri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e226095</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loeb</surname></persName>
		</author>
		<idno type="DOI">10.1097/SLA.0b013e318214b7e4</idno>
		<ptr target="https://doi.org/10.1097/SLA.0b013e318214b7e4"/>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="48" to="e54"/>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Perioperative antibiotic prophylaxis to prevent surgical site infections in solid organ transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Anesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Blumberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Abbo</surname></persName>
		</author>
		<idno type="DOI">10.1097/TP.0000000000001848</idno>
		<ptr target="https://doi.org/10.1097/TP.0000000000001848"/>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="21" to="e34"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge</title>
		<author>
			<persName><forename type="first">G</forename><surname>Santoro-Lopes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>De Gouvêa</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v20.i20.6201</idno>
		<ptr target="https://doi.org/10.3748/wjg.v20.i20.6201"/>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="6201" to="e6210"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Multidrug-resistant gramnegative bacteria infections in solid organ transplantation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Duin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Delden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Practice</forename><surname>Astidco</surname></persName>
		</author>
		<idno type="DOI">10.1111/ajt.12096</idno>
		<ptr target="https://doi.org/10.1111/ajt.12096"/>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="31" to="e41"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Satlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciu052</idno>
		<ptr target="https://doi.org/10.1093/cid/ciu052"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1274" to="1e83"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bodro</surname></persName>
		</author>
		<author>
			<persName><surname>Sab E N</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tubau</surname></persName>
		</author>
		<author>
			<persName><surname>Llad O L</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baliellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonz Alez-Costello</surname></persName>
		</author>
		<idno type="DOI">10.1097/TP.0000000000000366</idno>
		<ptr target="https://doi.org/10.1097/TP.0000000000000366"/>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="616" to="e622"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study</title>
		<author>
			<persName><forename type="first">I</forename><surname>Oriol</surname></persName>
		</author>
		<author>
			<persName><surname>Sab E N</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Simonetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Llad O L, Manonelles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonz Alez</surname></persName>
		</author>
		<idno type="DOI">10.1111/tri.12984</idno>
		<ptr target="https://doi.org/10.1111/tri.12984"/>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="903" to="e913"/>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Patel</surname></persName>
		</author>
		<idno type="DOI">10.1002/lt.24486</idno>
		<ptr target="https://doi.org/10.1002/lt.24486"/>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1143" to="1e53"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1399-3062.2009.00421.x</idno>
		<ptr target="https://doi.org/10.1111/j.1399-3062.2009.00421.x"/>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="405" to="e412"/>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Development of a risk prediction model for carbapenem-resistant Enterobacteriaceae infection after liver transplantation: a multinational cohort study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Abdala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mularoni</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciab109</idno>
		<ptr target="https://doi.org/10.1093/cid/ciab109"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="955" to="e66"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>De Gouvêa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Basto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Gonçalves</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2334-12-351</idno>
		<ptr target="https://doi.org/10.1186/1471-2334-12-351"/>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">351</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Gillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Silveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Massih</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0052349</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0052349"/>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">52349</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Pseudomonas Aeruginosa infection among liver transplant recipients: a clinical analysis of 15 cases</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Q</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Q</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">F</forename><surname>Ye</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.transproceed.2016.03.052</idno>
		<ptr target="https://doi.org/10.1016/j.transproceed.2016.03.052"/>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="2130" to="e2134"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Multidrug-resistant gram-negative bacterial infections in solid organ transplant recipients-guidelines from the American society of transplantation infectious diseases community of practice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pouch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Practice</forename><surname>Astidco</surname></persName>
		</author>
		<idno type="DOI">10.1111/ctr.13594</idno>
		<ptr target="https://doi.org/10.1111/ctr.13594"/>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">13594</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">ESBL-producing Enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pilmis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scemla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Join-Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Mamzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Lortholary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Legendre</surname></persName>
		</author>
		<idno type="DOI">10.3109/23744235.2015.1051107</idno>
		<ptr target="https://doi.org/10.3109/23744235.2015.1051107"/>
	</analytic>
	<monogr>
		<title level="j">Infect Dis (Lond)</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="714" to="e718"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation</title>
		<author>
			<persName><forename type="first">B</forename><surname>Coiffard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Prud'homme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hraiech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cassir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Pavec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<idno type="DOI">10.1186/s12890-020-1151-9</idno>
		<ptr target="https://doi.org/10.1186/s12890-020-1151-9"/>
	</analytic>
	<monogr>
		<title level="j">BMC Pulm Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">109</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Antimicrobial prophylaxis in liver transplant patients-A multicenter survey endorsed by the European Liver and Intestine Transplant Association</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vandecasteele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Waele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vandijck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vogelaers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Rogiers</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1432-2277.2009.00974.x</idno>
		<ptr target="https://doi.org/10.1111/j.1432-2277.2009.00974.x"/>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="182" to="e90"/>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Amikacin prophylaxis and risk factors for surgical site infection after kidney transplantation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Antonopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Piovesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Moura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>De Paula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Spadão</surname></persName>
		</author>
		<idno type="DOI">10.1097/TP.0000000000000381</idno>
		<ptr target="https://doi.org/10.1097/TP.0000000000000381"/>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="521" to="e527"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Carbapenemase-producing Klebsiella pneumoniae colonization and infection in solid organ transplant recipients: a single-center, retrospective study</title>
		<author>
			<persName><forename type="first">N</forename><surname>Pagani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Corcione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lupia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Scabini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Filippini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Angilletta</surname></persName>
		</author>
		<idno type="DOI">10.3390/microorganisms9112272</idno>
		<ptr target="https://doi.org/10.3390/microorganisms9112272"/>
	</analytic>
	<monogr>
		<title level="j">Microorganisms</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Complications after prostate biopsy: data from SEER-Medicare</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loeb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Berndt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Schaeffer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.juro.2011.06.057</idno>
		<ptr target="https://doi.org/10.1016/j.juro.2011.06.057"/>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="1830" to="e1834"/>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Wagenlehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Oostrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Tandogdu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Çek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grabe</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2012.06.003</idno>
		<ptr target="https://doi.org/10.1016/j.eururo.2012.06.003"/>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="521" to="e527"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis for transrectal prostate biopsy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Zani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rodrigues</forename><surname>Netto</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<idno type="DOI">10.1002/14651858.CD006576.pub2</idno>
		<ptr target="https://doi.org/10.1002/14651858.CD006576.pub2"/>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="page">6576</biblScope>
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: Implications for prophylaxis and treatment of infections after biopsy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Batura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Nielsen</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1464-410X.2010.09294.x</idno>
		<ptr target="https://doi.org/10.1111/j.1464-410X.2010.09294.x"/>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1017" to="e1020"/>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Liss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chang</forename><forename type="middle">A</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nakama-Peeples</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Osann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.juro.2010.11.088</idno>
		<ptr target="https://doi.org/10.1016/j.juro.2010.11.088"/>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="1283" to="e1288"/>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use</title>
		<author>
			<persName><forename type="first">U</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Amoroso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Challacombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pilcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kirby</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1464-410X.2011.10561.x</idno>
		<ptr target="https://doi.org/10.1111/j.1464-410X.2011.10561.x"/>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="1781" to="e1785"/>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate</title>
		<author>
			<persName><forename type="first">G</forename><surname>Losco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Studd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Blackmore</surname></persName>
		</author>
		<idno type="DOI">10.1111/bju.12590</idno>
		<ptr target="https://doi.org/10.1111/bju.12590"/>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="69" to="e72"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Transrectal prostate biopsyassociated prophylaxis and infectious complications: report of a query to the emerging infections network of the infectious diseases society of America</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Polgreen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Beekmann</surname></persName>
		</author>
		<idno type="DOI">10.1093/ofid/ofv002</idno>
		<ptr target="https://doi.org/10.1093/ofid/ofv002"/>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">2</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Redondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meil An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>García-Tello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ram</forename><surname>De Fata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Angulo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.acuro.2014.01.002</idno>
		<ptr target="https://doi.org/10.1016/j.acuro.2014.01.002"/>
	</analytic>
	<monogr>
		<title level="j">Actas Urol Esp</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="391" to="e396"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">High prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Horcajada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Busto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sorli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Terradas</surname></persName>
		</author>
		<author>
			<persName><surname>Salvad O M</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.urology.2009.06.061</idno>
		<ptr target="https://doi.org/10.1016/j.urology.2009.06.061"/>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1195" to="e1199"/>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy</title>
		<author>
			<persName><forename type="first">N</forename><surname>Suwantarat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Dumford 3rd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ponce-Terashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kundrapu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Zabarsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.1086/671734</idno>
		<ptr target="https://doi.org/10.1086/671734"/>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="973" to="e976"/>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Rectal swab culture-directed antimicrobial prophylaxis for prostate biopsy and risk of postprocedure infection: a cohort study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mermel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pareek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schiff</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.urology.2014.09.035</idno>
		<ptr target="https://doi.org/10.1016/j.urology.2014.09.035"/>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="8" to="e14"/>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Routine ertapenem prophylaxis for transrectal ultrasound guided prostate biopsy does not select for carbapenem resistant organisms: a prospective cohort study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Bloomfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mclachlan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Studd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Blackmore</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.juro.2017.03.077</idno>
		<ptr target="https://doi.org/10.1016/j.juro.2017.03.077"/>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">198</biblScope>
			<biblScope unit="page" from="362" to="e368"/>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cussans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Somani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Basarab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Dudderidge</surname></persName>
		</author>
		<idno type="DOI">10.1111/bju.13402</idno>
		<ptr target="https://doi.org/10.1111/bju.13402"/>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="725" to="e731"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a metaanalysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Liss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sar</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Roberts</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00345-018-2217-7</idno>
		<ptr target="https://doi.org/10.1007/s00345-018-2217-7"/>
	</analytic>
	<monogr>
		<title level="j">World J Urol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1007" to="e1017"/>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pilatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dimitropoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Veeratterapillay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Omar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maclennan</surname></persName>
		</author>
		<idno type="DOI">10.1097/JU.0000000000000814</idno>
		<ptr target="https://doi.org/10.1097/JU.0000000000000814"/>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="224" to="e230"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Reducing infectious complications following transrectal ultrasound-guided prostate biopsy: a systematic review</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Singla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Roehrborn</surname></persName>
		</author>
		<idno type="DOI">10.3909/riu0713</idno>
		<ptr target="https://doi.org/10.3909/riu0713"/>
	</analytic>
	<monogr>
		<title level="j">Rev Urol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="73" to="e89"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">A prospective randomized trial comparing a combined regimen of amikacin and levofloxacin to levofloxacin alone as prophylaxis in transrectal prostate needle biopsy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kanamaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kamiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sengiku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Iguchi</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/pubmed/26945658"/>
	</analytic>
	<monogr>
		<title level="j">Urol J</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2533" to="e2540"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Trial Comparing a Combined regimen of amikacin and ciprofloxacin to ciprofloxacin alone as transrectal prostate biopsy prophylaxis in the era of high fluoroquinoloneresistant rectal flora</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.3346/jkms.2018.33.e113</idno>
		<ptr target="https://doi.org/10.3346/jkms.2018.33.e113"/>
	</analytic>
	<monogr>
		<title level="j">J Korean Med Sci</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">113</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Rectal culture-based versus empirical antibiotic prophylaxis to prevent infectious complications in men undergoing transrectal prostate biopsy: a randomized, non-blinded multicenter trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Tops</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kolwijck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Koldewijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Somford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Delaere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciac913</idno>
		<ptr target="https://doi.org/10.1093/cid/ciac913.ciac913"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<monogr>
		<title level="m">100European Association of Urology (EAU). EAU guidelines on urological infections</title>
		<meeting><address><addrLine>Arnhem, The Netherlands</addrLine></address></meeting>
		<imprint>
			<publisher>EAU Guidelines Office</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jacewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Günzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sandbaek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Magheli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Busch</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(22)00373-5</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(22)00373-5"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1465" to="1e71"/>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 Update by the Infectious Diseases Society of America</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Nicolle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Colgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Demuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Drekonja</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciz021</idno>
		<ptr target="https://doi.org/10.1093/cid/ciz021"/>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1611" to="e1615"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Bacteria of preoperative urinary tract infections contaminate the surgical fields and develop surgical site infections in urological operations</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hamasuna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Betsunoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sueyoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yakushiji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tsukino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nagano</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1442-2042.2004.00941.x</idno>
		<ptr target="https://doi.org/10.1111/j.1442-2042.2004.00941.x"/>
	</analytic>
	<monogr>
		<title level="j">Int J Urol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="941" to="e947"/>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Trends in antibiotic resistance in urologic practice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kandil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cramp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vaghela</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.euf.2016.09.006</idno>
		<ptr target="https://doi.org/10.1016/j.euf.2016.09.006"/>
	</analytic>
	<monogr>
		<title level="j">Eur Urol Focus</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="363" to="e73"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Therapeutic failures of targeted antibiotic prophylaxis in urology</title>
		<author>
			<persName><forename type="first">E</forename><surname>Curlier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sadreux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Markowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Brureau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Donat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Blanchet</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10096-021-04329-9</idno>
		<ptr target="https://doi.org/10.1007/s10096-021-04329-9"/>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="299" to="e304"/>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Mahajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Ariza-Heredia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Rolston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Graviss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Aloia</surname></persName>
		</author>
		<idno type="DOI">10.1245/s10434-013-3294-x</idno>
		<ptr target="https://doi.org/10.1245/s10434-013-3294-x"/>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="513" to="e519"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Leng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Z</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Shen</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dku302</idno>
		<ptr target="https://doi.org/10.1093/jac/dku302"/>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="3379" to="3e86"/>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Oral decontamination with colistin plus neomycin in solid organ transplant recipients colonized by multidrugresistant Enterobacterales: a multicentre, randomized, controlled, openlabel, parallel-group clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Fariñas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gonz</forename><surname>Alez-Rico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Fern</forename><surname>Andez-Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fortún</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Escudero-Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2020.12.016</idno>
		<ptr target="https://doi.org/10.1016/j.cmi.2020.12.016"/>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="856" to="e63"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial)</title>
		<author>
			<persName><forename type="first">Gsa</forename><surname>Abis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hbac</forename><surname>Stockmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Bonjer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Van Veenendaal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mlm</forename><surname>Van Doorn-Schepens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Budding</surname></persName>
		</author>
		<idno type="DOI">10.1002/bjs.11117</idno>
		<ptr target="https://doi.org/10.1002/bjs.11117"/>
	</analytic>
	<monogr>
		<title level="j">Br J Surg</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="355" to="e63"/>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Association of mechanical bowel preparation and oral antibiotics before elective colorectal surgery with surgical site infection: a network metaanalysis</title>
		<author>
			<persName><forename type="first">Jwt</forename><surname>Toh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hitos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pathma-Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>El-Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Richardson</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2018.3226</idno>
		<ptr target="https://doi.org/10.1001/jamanetworkopen.2018.3226"/>
	</analytic>
	<monogr>
		<title level="j">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">183226</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial</title>
		<author>
			<persName><forename type="first">Espin</forename><surname>Basany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Solís-Peña</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pellino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kreisler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fraccalvieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Muinelo-Lorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/S2468-1253(20)30075-3</idno>
		<ptr target="https://doi.org/10.1016/S2468-1253(20)30075-3"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="729" to="e738"/>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">A bundle that includes active surveillance, contact precaution for carriers, and cefazolin-based antimicrobial prophylaxis prevents methicillin-resistant Staphylococcus aureus infections in clean orthopedic surgery</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kawamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsumoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shigemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nozima</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajic.2015.09.014</idno>
		<ptr target="https://doi.org/10.1016/j.ajic.2015.09.014"/>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="210" to="e214"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective</title>
		<author>
			<persName><forename type="first">B</forename><surname>Allegranzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bischoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Z</forename><surname>Kubilay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Jonge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Vries</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(16)30402-9</idno>
		<ptr target="https://doi.org/10.1016/S1473-3099(16)30402-9"/>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="288" to="e303"/>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Menz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Charani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajm</forename><surname>Leather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Moonesinghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Phillips</surname></persName>
		</author>
		<idno type="DOI">10.2147/IDR.S319780</idno>
		<ptr target="https://doi.org/10.2147/IDR.S319780"/>
	</analytic>
	<monogr>
		<title level="j">Infect Drug Resist</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="5235" to="5e52"/>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>